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Background: To maintain the balance between muscle anabolism and catabolism by 
influencing the muscle protein synthesis and degradation is crucial to several catabolic diseases 
to avoid muscle wasting. Previous studies have proposed that marine protein hydrolysates 
(MPH) have an increased influence on protein synthesis through faster absorption compared to 
whole proteins like whey, along with positive bioactive functions and other health benefits. 
 
Aim: The overall aim of this thesis is to investigate whether an intake of 20 mg/kg body weight 
of MPH made from Atlantic cod could have a potential impact on biomarkers related to muscle 
synthesis and degradation following exhaustive endurance cycling in healthy males.  
 
Methods: This intervention study was performed as a double blind, randomized, placebo-
controlled pilot study with crossover design divided into three phases over three separate test 
days. In total, 14 healthy male volunteers, medium trained and between 40 to 58 years of age 
were recruited.  Phase one consisted of physical assessment and a maximal exercise test. Phase 
two and three involved the intervention where participants preformed two exhaustive endurance 
cycling sessions and the ingestion of the intervention drink. The intervention drinks were either 
MPH or placebo and was only ingested after the first session followed by a standardized meal. 
Collection of urine was performed to analyze the nitrogen balance, 1-Methylhistidine (1-MH), 
3-Methylhistidine (3-MH) and the ratio between 3-MH and creatinine (3-MH/ Creatinine). 
Blood were collected within the same time intervals throughout both test days whereas 1-MH, 
3-MH, creatinine, creatine kinase (CK) and retinol-binding protein 4 (RBP4) were all analyzed.  
 
Results: Urine analysis showed no significant differences between the intake of MPH 
compared to placebo in nitrogen metabolized (p = 0.315), nor in the 3-MH/ Creatinine ratio (p 
= 0.066). The ratio between 1-MH and 3-MH (1- MH/ 3-MH) gave a significant result (p = 
0.028), however multiple testing showed no significant difference (p = 0.107). Linear mixed 
regression analysis of blood resulted in no significant difference between the two drinks in CK 
(p = 0.823), 1-MH/ 3-MH (p = 0.595), 3-MH/ Creatinine (p = 0.662) nor RBP4 (p = 0.052).  
 
Conclusion: This study has demonstrated the need to further explore and investigate the use of 
MPH as a supplement to increase muscle synthesis and decrease muscle degradation in humans. 
Even though this study did not find any significant effect of a single dose containing small 
amounts of MPH on muscle synthesis and degradation, several results did suggest that there 
might be improvement through increased protein synthesis with the usage of MPH.  
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Anabolism and catabolism are parts of the body’s metabolism where both act at the same time 
to balance each other. Imbalance between the two could lead to changes in body weight and 
composition (1). In an anabolic state, the cellular process builds complex molecules from 
simple molecules to increase or maintain muscle mass. This refers to a state in skeletal muscles 
where synthesis exceeds degradation (1). A catabolic state on the other hand is the opposite 
whereas metabolic processes break down complex molecules to simple molecules reducing 
both total fat- and muscle mass. Referred to as state in skeletal muscle tissue where degradation 
exceeds synthesis (1).  
 
1.1 MUSCLE SYNTHESIS AND DEGRADATION 
The metabolic basis of skeletal muscle growth lies in the relationship between the rates of 
muscle protein synthesis and muscle protein degradation (2). Expansion of muscles, also termed 
muscle hypertrophy, is only possible when net protein synthesis occurs (when muscle protein 
synthesis exceeds degradation) (3). In order to stay healthy, the synthesis of muscle protein is 
essential to the ongoing growth, maintenance and repair of body tissue (4). On a daily basis, 
skeletal muscles are exposed to different types of stress that could have a major or minor impact 
on muscle synthesis. Two important kinds of stress are physical activity and chronic disease. 
 
1.1.1 Physical activity 
During physical activity skeletal muscles are often exposed to a great load of stress (3). In all 
muscular activity, catabolism of the muscle will naturally begin and cannot be stopped (5). 
Further, as long as a greater amount of protein is available and synthesized at the same time, 
muscles will be developed and not reduced. Muscular activity and protein synthesis are 
prerequisite to have a significant development of muscle (5). Through adolescence the synthesis 
is peaking by the rapid rate of growth of the body, which significantly slows down after 
reaching roughly 20 years of age. Past this point, muscles will not grow or be strengthened 
though either sedentary activity, the consumption of particular foods nor supplements alone (5).  
 
Several factors could influence protein requirements in athletes; what kind of exercise, volume, 
duration and state of training (6, 7), energy density of the diet (8), and carbohydrate content (9) 
are all relevant factors contributing to this calculation. Research on muscle synthesis and 
degradation related to physical activity focuses on the type of protein, protein in combination 
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with carbohydrates and at what time and what rate anabolism occurs compared to catabolism 
(5).  
 
1.1.2 Chronic diseases 
Considering the body is under a lot of stress during chronic diseases, catabolic diseases with 
rapid weight loss often follows (11, 12). Controlled regulation of muscle mass by maintaining 
the balance between synthesis and degradation is crucial to several catabolic diseases and 
unloading to avoid muscle wasting. Muscle wasting, which can lead to severe pathological 
progression in various diseases and aging, is the result of a decreased rate of protein synthesis 
and an accelerated rate of protein degradation in skeletal muscles (12). Even though a large 
portion of protein is stored in the muscles and viscera, the body must strive to protect it from 
being used as an energy source. During metabolic stress, the body will draw protein out of 
muscles to meet its needs in contrast to healthy conditions or normal deficits where additional 




Figure 1: Associated complications to loss of lean muscle mass. 
Modified figure from article by Argilies J.M. et.al. (13). The figure shows how pathological 
progression creates further complications. Already at 10% decreased muscle mass we can see 
that immunity are decreased and there is an increased risk of infection. This could be crucial 
to a person who are already struggling with other illnesses or has reduced health because of 
other age-related health conditions.  
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Monitoring and assessment of protein and energy nutritional status are also essential to prevent, 
diagnose and treat protein and energy wasting (PEW). A condition highly prevalent and 
strongly correlated with increased morbidity and mortality in multiple patient populations (10, 
11, 14). PEW is defined as decreased fat mass, reduced somatic protein mass and/or reduced 
protein pool along with reduced protein and energy intake (11). Monitoring and assessment of 
PEW is broad and complex, involving indirect measures of visceral protein concentrations, 
somatic protein stores, energy expenditure and requirements, as well as precise measurements 
of protein and energy homeostasis (10).  
 
Dietary protein plays a significant role improving muscle protein anabolism and reducing 
muscle protein catabolism (15, 16). Considering this, optimizing intake and the quality of 
protein should be a high priority during treatment and prevention of muscle wasting. Previous 
studies have shown some dietary proteins to be more effective than others. Emerging data have 
found indications of protein hydrolysates to be significantly more effective at a lower level than 
that of the whole protein (17, 18). With this in mind, further research is important regarding 
this area which could improve life quality, health outcomes, and life expectancy in several 
population groups.  
 
1.2 PROTEIN 
The levels of protein in the body is relatively constant throughout the lifespan, despite 
quantitative and qualitative variations in dietary protein intake (19). Proteins are nitrogen-
containing substances that are formed in chains of amino acids and serve as the major structural 
component of muscles and other tissues in the body. About 10 kilograms of an adult body 
consist of  protein, where approximately 70 % consist of muscle (20).  
 
In total 20 amino acids are identified needed for human growth and metabolism. Twelve of 
these are termed nonessential, meaning that they can be synthesized by our body. The body are 
not able to synthesize the remaining eight amino acids, which needs to be consumed through 
our diets described as essential amino acids. Absence of any of these amino acids will 
compromise the ability to meet nitrogen and amino acid requirements of growth and 





1.2.1 Protein turnover 
The net result of continuous synthesis and degradation of body protein is referred to as protein 
turnover, which ensures maintenance of optimally functioning proteins as a fundamental 
biological process (21). To make this process run smoothly, the body is reliant on the 
availability of protein from the protein pool. Expansion of the protein pool occur either through 
decreased synthesis, increased degradation or increased dietary protein intake. By contrast, 
protein pool contraction occur when synthesis increases, degradation decreases or reduced 




Figure 2: Estimated daily turnover of protein in the body based on a 70 kg male. 
Modified figure from published paper by Hellerstein M.K. et.al (23). This figure shows an 
approximation of how the proteins could be distributed around in the body to be utilized to 






1.2.2 Functions  
All amino acids are based on a common structure consisting of one amino group (NH2), one 
organic acid group (COOH), a single hydrogen atom (H), and a side chain (R) all attached to a 
central carbon atom (24). The side chain is the special component that provides the 
distinguishing feature. Chains of amino acids differ in length from about 20 amino acid units 
to many thousands of units. They may be linear or branched and can form complex three-
dimensional arrangements. This variety in length and shape of the amino acid chain, including 
the numerous permutations of the constituent amino acid units, give rise to the wide diversity 
of proteins in the body with a broad set of functions (25). These functions of protein could be 
divided into regulatory, structural and energy serving functional groups which are listed in 
Table 1. 
 
1.2.3 Urea cycle  
Amino acids from both the diet and the body´s own muscles and tissues are broken down 
through oxidation (27). During this oxidation process in the liver, ammonia is formed. The urea 
cycle mainly occurs in the liver and converts highly toxic ammonia to urea (27). Urea is then 
released into the bloodstream where it travels to the kidneys and is ultimately excreted in the 
urine. If proper ratios of amino acids are not present at the right time and the body has no 
possibility of storing amino acids, some amino acids will become oxidized and the nitrogen 
will be excreted in the urine as urea (27). The body must be supplied with amino acids to replace 




Table 1: Protein functions in the human body divided in regulatory, structural and energy serving functional groups. 
Group Function Description Example 
Regulatory ▪ Enzymes Enzymes are proteins that aid the thousands of biochemical reactions that take place 
within and outside of body cells 
▪ Digestion 
▪ Energy production 
▪ Blood clotting 
▪ Muscle contraction  
 ▪ Hormones Chemical messengers that aid communication between your cells, tissues and organs.  ▪ Insulin 
▪ Glucagon 
▪ Human growth hormone (hGH) 
▪ Antidiuretic hormone (ADH) 
▪ Adrenocorticotropic hormone (ACTH) 
 
 ▪ Maintains 
proper pH 
Proteins play a vital role in regulation the concentrations of acids and bases in the 
blood and other body fluids. 
▪ Haemoglobin 
 ▪ Balances fluids Regulation of body processes to maintain fluid balance. ▪ Albumin 
 
 ▪ Immune health Support forming antibodies ▪ Globulin 
 
 ▪ Transport 
nutrients 
Transport proteins carry substances throughout the bloodstream – into cells, out of cells 
or within cells. 
▪ Haemoglobin 
▪ Glucose transporters (GLUT) 
▪ Lipoproteins 
 
 ▪ Stores nutrients Protein also stores different kinds of nutrients like iron. ▪ Ferritin 
▪ Casein 
Structural ▪ Growth and 
Maintenance 
 
Under normal circumstances, the body breaks down the same amount of protein that it 
uses to build and repair tissue. 
▪ Muscle 
▪ Connective tissue 
▪ Numerous specialist cells 
 
 ▪ Keratin 
▪ Collagen 
▪ Elastin 
Some proteins are fibrous and provide cells and tissues with stiffness and rigidity. ▪ Hair, skin and nails 
▪ Bones, ligaments, tendons and skin 
▪ Uterus, lungs and arteries 
Energy ▪ Supply the 
body with 
energy 
Proteins can also be used as energy; however, they are not the primary choice as an 
energy source. Amino acids from protein supplied in addition to what is needed to build 
proteins will be used as an energy source, mainly by being oxidized in the liver through 
the urea cycle.  
▪ Fasting 
▪ Exhaustive exercise 
▪ Inadequate calorie intake 




1.3 MARINE PROTEIN HYDROLYSATE  
The fact is that protein nutrition is complex. In addition to the amount of protein, multiple other 
factors could play a significant role in protein synthesis. First, proteins from different sources 
vary in rates of absorption and quality (51, 52). So far studies have considered whey protein to 
be the superior one, especially in athletes because of the building and recovery of muscle 
potential (21, 25). Secondly, proteins could be manipulated and hydrolysed meaning that the 
protein is broken into peptides. These peptides have been considered to have a more rapid 
uptake and availability in the body compared to whole proteins (53). Thirdly, as hydrolysed 
proteins could be significant faster absorbed than intact proteins, they may affect the secretion 
of hormones like insulin differently from other proteins (53). It is reason to believe that 
hydrolysed proteins are superior to intact proteins and free amino acids in terms of skeletal 
muscle protein anabolism (54-56).  
 
1.3.1 Protein hydrolysate 
Protein hydrolysates (PH) are produced from purified protein sources by heating with acid or 
preferably, addition of proteolytic enzymes followed by purification procedures (54). Each PH 
is a complex mixture of peptides of different chain length providing mainly di- and tripeptides 
together with free amino acids. Approximately 60% of dietary protein ingested is absorbed 
along the intestine as di- and tripeptides and have a greater resistance to gastric acid and heat 
(57). In addition, they are said to be absorbed along a separate route than free amino acids, 
which could be one explanation of why they might be easier absorbed and taken advantage of 
in the body (58). Studies have shown that especially hydrolysates of marine proteins have 
bioactive functions, and positive health effects have been noted in several areas (59). 
 
1.3.2 Marine protein 
There is a high potential in marine bioprocessing industries to convert and utilize marine food 
products and their bi-products as valuable functional ingredients (51). Hydrolysed proteins 
from fish, marine protein hydrolysates (MPH), have gradually gained more attention due to 
potential valuable health-related outcomes. Substantial effects of hydrolysed fish proteins on 
metabolism have been shown in rats (60-62). Marine proteins are leucine rich and well balanced 
in other essential amino acids (53, 63). Inspired by this, two randomized controlled trial studies 
with crossover design and great similarities in methods, investigated effects of MPH ingestion 
during endurance cycling in men (64, 65). Vegge et al. found no influences of MPH on 
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metabolism. They did however find improved cycling performance in those participants with 
the lowest exercise capacity, and thus indicated that MPH provided ergogenic effects in less 
trained athletes (65). On the other hand, results found by Siegler et al. demonstrated metabolic 
influences of MPH but did not find effects on performance (64).  
 
Furthermore, proteins from seafood may have properties different from those in meat (52). In 
an intervention study using a crossover design, healthy volunteers consumed meals with similar 
compositions with exception of the protein source (52). Distribution of fat, carbohydrates and 
protein were equal in the diet, and in the meals containing meat, cod liver oil was added to 
balance the long-chained fatty acids in fish. In the study group of which the protein source was 
fish, researchers found decreased risk factors of cardiovascular disease providing evidence 
favoring fish to have health benefits. Also, another study showed that 4 weeks of 
supplementation of 3g fish protein tablets increased the percentage of muscle and decreased the 
percentage of body fat in overweight adults (66). 
 
1.3.3 Potential health-related outcomes 
In everyday life the human body constantly undergoes physiological imbalances and are 
exposed to extrinsic toxic substances on a regular basis that can disturb mandatory functions. 
This disturbance could lead to various health problems (67). Meanwhile a lot of processed foods 
and changes to the raw product cause physical, biological and chemical food spoilage or loss 
of nutrition characteristics, hydrolysis of proteins to peptides could actually be more beneficial 
in the body (51). MPH have exhibited potent biological activities like antimicrobial, antiviral, 
antitumor/cytotoxic, antihypertensive/angiotensin-I converting enzyme (ACE) inhibitory, 
antioxidant, cardiovascular protective, immunomodulatory neuropeptides, neuroprotective, 
anti-diabetic, appetite suppressing and other bioactivities (51, 59, 68).  
 
From a nutrition point of view, marine sources compared to other diet sources provide the 
favorable fatty acid composition EPA (Eicosatetraenoic acid) and DHA (Docosahexaenoic 
acid) proven to have health benefits (51). Considering the bioactivity’s mentioned above, some 
MPH or their derivates attract the attention of the pharmaceutical and nutraceutical industry, 
attempting to designing them to be used in treatment or prevention of various diseases (59, 68). 
A large number are already in different phases of the clinical and preclinical run, but there is 




1.4 ASSESSMENT OF MUSCLE PROTEIN SYNTHESIS AND DEGRADATION  
Protein's unique function in supporting cellular growth and development elevates its 
significance in nutrition assessment.  No specific laboratory value can determine the precise 
protein status of an individual, and each test has its own limitations. Therefore multiple different 
measurements are required hence no single method to assess nutritional status and responses to 
nutritional intervention can be considered as a “gold standard” (10, 28). Some commonly used 
measures are the following: 
 
1.4.1 Somatic Protein status 
Somatic protein status is considered measures of the skeletal muscles. Such measures could be 
both anthropometric or biochemical in the form of excreted biomarkers linked to muscle 
degradation in urine or blood (10).  
 
1.4.1.1 Bioelectrical impedance analysis  
Bioelectrical impedance analysis (BIA) is a technique proven to be safe, easy to use, and 
generally acceptable to patients. It is an indirectly measure of the body composition used for 
determining fluid management, but the use has also increased to evaluate protein-energy status 
(29). The principle behind is based on a two-compartment model that determines total body 
water (TBW) and soft tissue (i.e. fat-free mass (FFM) and fat mass (FM)) by using electrical 
currents. Electrical currents are sent through the body between electrodes attached on the ankles 
and wrists, or by standing barefoot on a BIA machine holding one handle in each hand. Lean 
body tissues, which contain body fluids and electrolytes, have highly conductive, low resistance 
electrical pathways. Skin, bone and fat, on the other hand, are very poor conductors and offer 
high resistance (10).  
 
Reactance is the opposition to the flow of electrical current due to the electrical capacitance 
such as is found in the cell membrane wall. Resistance is defined as the extra-cellular and intra-
cellular fluid content, while the reactance is based on the cell membrane content (30). In FFM, 
these fluid compartments are parallel components separated by cell membranes; therefore, 
parallel models are more accurate for determining their impedance (30).  
The relationship between reactance and resistance is called the phase angle (10).  Each person’s 
phase angle is a direct measurement of their cell membrane integrity, and the distribution of 
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water within and outside the cell. It gives an indicator of good health by increasing when there 
are large quantities of intact cell membranes in the skeletal muscle and body cell mass. 
Moreover, the phase angle will decrease when a person is ill and cell membranes have been 
attacked. With increased age, the phase angle also decreases, but if you manage to increase the 
phase angle, aging is slowed down (30). This device might be superior by its ability to identify 
patients who have clinically important PEW and a poor prognosis.  
 
1.4.1.2 Nitrogen 
Nitrogen is a fundamental main body component of amino acids which the significant amount 
in the diet is bound in protein (25). It is required for both the production of several nitrogenous 
compounds involved in a variety of functions (immune mediators, hormones, antioxidant 
defenses, neurotransmitters etc.) and protein synthesis (19). Thus, the nitrogen content should 
be both qualitatively and quantitatively normal as well as normally maintained to ensure normal 
body functions (31).  
 
Nitrogen homeostasis is achieved via complex series of changes to the rates of body protein 
turnover, amino acid oxidation, urea production and nitrogen excretion that occur during the 
postprandial and post absorptive periods of the day (31). Respectively, measuring nitrogen 
intake and loss can be used to study protein metabolism and give a measure of protein balance 
by analysis of the nitrogen content in urine. Nitrogen balance is commonly divided into three 














Table 2: Basic states commonly used about nitrogen balance. 
Basic state Description 
Positive  When nitrogen uptake exceeds the excretion and there is an increase in the total body pool of 
protein, we are talking about a positive nitrogen balance. This state is associated with periods 
of growth, hyperthyroidism, tissue repair, at rehabilitation centers following abnormal diseases, 
and pregnancy. It is the optimal state of muscle growth called the anabolic state of the body.  
Equilibrium This state represents the normal state where uptake and excretion of nitrogen are equal, the 
perfect balance of nitrogen in the body to maintain steady-state. Healthy adults eating a 
balanced diet. 
 
Negative  Where nitrogen excretion exceeds nitrogen uptake and the body is turned to a catabolic state. 
The organism loses tissue, nitrogen is drawn away from muscle where it is needed for growth 
and from vital organs where serious damage can occur. A negative nitrogen balance could be 
used as a part of clinical evaluation of malnutrition, and are associated with serious tissue 
injuries, wasting diseases, burns, hyperthyroidism, fever, and during periods of fasting.  
 Reference: Article published by Tessari P. (31). 
 
A neutral nitrogen balance, defined as the equilibrium between intake and loss of nitrogen, is 
essential in order to maintain good health (31). It is all relying on two main parts of the 
metabolism; anabolism and catabolism which anabolism usually is highly dependent on dietary 
nutrient intake. A dietary protein intake (DPI) of 0.6 g/kg/day is considered sufficient to achieve 
equilibrium in most adults, when adequate energy intake and protein with a high biological 
value is ingested (19, 32). On the other hand, compensatory mechanisms allowing more 
efficient utilization of nutrients through a reduction in protein breakdown and amino acid 
oxidation are activated if protein and energy requirements are not met through the diet (33, 34).  
 
The adequacy of protein intake can be determined on behalf of a positive or negative protein 
balance in patients. However, in most cases direct and precise measures of nitrogen balance are 
not yet available, and indirect measures of protein balance through estimates of net protein 
utilization (NPU) is necessary (10).  A common method used as an indicator involves measuring 
urine urea nitrogen loss - as 90% of nitrogen is lost through the urine via the kidneys (31). It is 
also very important to know exactly how much protein the person have consumed to make a 
correct estimation by using metabolized nitrogen from the urine result. However, there could 
be differences in excretion following protein quality. Diets containing poor quality protein have 
been  associated with an increased nitrogen losses due to the inefficient utilization of 
indispensable amino acids (35). 
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1.4.1.3 Creatine kinase  
Creatine kinase (CK), formerly known as creatine phosphokinase is an intracellular enzyme 
present in great amounts in the brain, myocardium, and skeletal muscle; smaller amounts occur 
in other visceral tissues (36, 37). Like other enzymes, CK is leaked into the bloodstream when 
a cell becomes damaged. If many cells are damaged at the same time, a detectable level of CK 
and other enzymes could occur in the blood. CK appear different according to the location it is 
leaked from making it a useful diagnostic tool to detect the damage muscle tissue which can 
further be used in diagnosis (36). A serum CK test can detect many conditions such as a heart 
attack, muscle breakdown, and even autoimmune diseases which are attacking certain organs 
and tissues (36, 37). 
 
On the other side, the small amount of CK that at a regular basis can be found in the blood 
comes primarily from skeletal muscles (36, 37). Any condition that causes muscle damage 
and/or interferes with muscle energy production or impact like strenuous exercise and 
inflammation of muscles (myositis) or muscle diseases (myopathies) such as muscular 
dystrophy can cause an increase of CK in the blood (37). Because of the many current assay 
methods in use, there is no standard reference value for serum CK  (36). Normal values are best 
determined locally based on the method employed and the range for healthy controls.  
 
1.4.1.4 3-Methylhistidine   
3-Methylhistidine (3-MH) is an integral part of myofibrillar proteins found in both actin and 
myosin (38). It is formed by methylation of histidine as a posttranslational modification of these 
myofibrillar proteins. 3-MH is liberated during degradation of myofibrillar protein, meaning it 
is not metabolized or used in protein synthesis, but excreted unchanged into the urine (39). As 
long as protein synthesis and degradation stay steady, the amount of 3-MH should reflect an 
image of the human body muscle mass. 3-MH has been shown to be elevated after physical 
exercise, arthritis, neuromuscular disorders, terminal stages of serious illness, muscular 
dystrophy, and muscle wasting (40). 
 
About 45% of the weight of an adult man is compromised by muscle (20). During conditions 
like injury and starvation, but also neuromuscular, endocrine and malignant disease muscle, 
mass falls rapidly (41). This rapid change in mass could be a result of both decreased synthesis 
or increased degradation. The rate of myofibrillar protein breakdown could theoretically be 
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measured with 3-MH analyzed from urine excretion, but changes in the rate of synthesis of 
muscle cannot be measured non-isotopically.  
 
As 3-MH in plasma or urine may serve as a marker of muscle degradation, it also reflects dietary 
meat intake (41, 42). Urinary 3-MH as an indicator of myofibrillar protein catabolism may be 
compromised in clinical studies, as patients cannot always make correct statements about their 
food intake. Furthermore, a 72hour meat-free period as the commonly recommended may be 
insufficient to guarantee that results are not compromised. Renal excretion could be impaired 
due to functional or organic disorders, or absorption and emptying can be delayed by an earlier 
meal containing meat (39). In addition, under normal conditions there is a interindividual 
variation of 3-MH excretion in man. Moreover, it is not necessarily easy to collect 24hour urine 
in patients precisely (42). 
 
On the other hand, studies have shown that in healthy adults we could get a pretty good estimate. 
Endogenous versus dietary 3-MH can be distinguished by simultaneous measurement of 1-
methylhistidine (1-MH) (39). That is built on several reasons where 1-MH is not formed in 
humans, but occurs in skeletal muscles of several other species, including dietary meat (39). 
These two parameters have the same halftime and similar dose-independent kinetics 
irrespective of dietary source. There is only a small intraindividual variation in their basal 
excretion, making it possible to separate and estimate the true excretion of 3-MH representing 
myofibrillar protein breakdown from skeletal muscle away from dietary meat intake with the 
1-MH/ 3-MH ratio (39, 40).  
  
Urinary excretion of 3-MH has been used to determine the rate of skeletal muscle degradation 
as mentioned above (41, 42, 44). However, the presence of 3-MH in the urine does not 
necessarily reflect the specific breakdown of myofibrillar protein since this amino acid is also 
released from tissues other than skeletal muscle (45). This method requires several hours of 
urine collection, and thus may not be useful to detect acute changes in the rate of skeletal protein 
degradation. Monitoring 3-MH in the plasma has also been evaluated as means of determining 
the rate of skeletal muscle degradation in addition to urine measures (45). This procedure is 
thought to be a more sensitive measure of identifying acute changes in the rate of myofibrillar 
degradation (45). However, the 3-MH present in the plasma may not be entirely of skeletal 
muscle origin either, as it has also been detected in cardiac and smooth muscle and may be 
affected by renal function or blood flow (45). 
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1.4.2 Visceral protein status 
Visceral protein concentrations refer to biochemical markers present in serum or plasma. These 
markers are circulating proteins that estimate the size of the visceral protein pool in the body 
(43). Almost all circulating visceral proteins have certain physiologic roles such as serving as 
carriers or binders, or having an active involvement in vital functions such as the immune 
system.  
 
1.4.2.1 Retinol-binding protein 4 
Retinol- binding protein 4 (RBP4) is an acute-phase respondent synthesized by the liver and 
serves as the transport protein for vitamin A which forms a complex with prealbumin in blood 
(46, 47). Once the vitamin has been delivered to the target cell, the molecule also loses its 
affinity for pre-albumin (48). The free RBP4 molecule is rapidly filtered at the glomerulus and 
catabolized in the renal tubules after reabsorption by the proximal tubular cells. RBP4 has the 
smallest body pool and shortest half-life (12hours) of the serum proteins (47, 49). 
Assessment of RBP4 is used to determine visceral protein mass in health-related nutritional 
studies (50). Theoretically, it is most likely better to reflect recent dietary intake of short-term 
changes and responses to nutrition support interventions, rather than an indicator of overall 
nutrition status considering the short half-time (49). RBP4 is considered to be one of the more 
sensitive indicators of protein status in the non-critical ill, where it is a measure of the protein 















1.5 AIM OF THE STUDY 
The overall aim of this thesis was to investigate whether intake of 20 mg/kg body weight (BW) 
of MPH made from Atlantic cod could have a potential impact on biomarkers related to muscle 
synthesis and degradation following exhaustive endurance cycling in healthy males. We wanted 
to explore if there was possibility that a single dose of MPH in addition to whey protein could 
be superior to whey protein alone at influencing these biomarkers.  
 
1.5.1 Hypothesis: 
H0: The intake of a single dose of 20 mg/kg BW of MPH will not show significant 
impact on biomarkers related to muscle synthesis and degradation. 
H1: The intake of a single dose of 20 mg/kg BW of MPH will show significant impact 
on biomarkers related to muscle synthesis and degradation.  
 
1.5.2 Research questions:  
1. Does a single dose of MPH have an impact on nitrogen balance related to muscle 
synthesis and degradation? 
2. Could a single dose of MPH influence the secretion of CK and 3-MH related to muscle 
degradation? 







2.1 STUDY DESIGN 
This intervention study was performed as a double blind, randomized, placebo-controlled pilot 
study with crossover design divided into three phases. The intervention was a collaboration 
conducted by The Department of Clinical Science and The Department of Physiotherapy at 
Haukeland University Hospital, University of Bergen and The Western Norway University of 
Applied Science. Data collections and analyzing were carried out from September 2017 to 
February 2019.  
 
2.2 RECRUITMENT OF PARTICIPANTS 
A total of 14 participants were estimated to be the decisive number needed in the study. This 
calculation was based on a power estimation of mean changes in blood glucose profile (area 
below the curve) of 20%, alpha of 0.05, 80% effect and a standard deviation (SD) of 10%. Due 
to a small sample size and the goal of achieving low variation with a homogeneous test group, 
women were not recruited in this study to avoid possible hormone and anthropometric 
differences. 
 
The recruitment was conducted by reaching out through advertising in social media, but also 
with an informing poster sent through email directly to different bicycle clubs in Bergen, July 
2017 (Appendix 1). All potential participants responding to the advertisement were screened 
according to the inclusion and exclusion criteria (Table 3) of the study through email. This 
resulted in 14 healthy male volunteers, medium trained with a total amount of 8-12 hours 
weekly training and cycling as their main exercise activity between 40 to 58 years of age were 
recruited.   
 
Participants recruited were primarily reached through email, except for a short message service 





Table 3: Study inclusion and exclusion criteria. 
          Inclusion criteria 
▪ Signed informed consent form (Appendix 2). 
▪ Willing to comply with all study procedures and be available for the length of the study.  
▪ The participant is a man between 40 to 58 years of age. 
▪ The participant has a BMI between 19-29. 
 
▪ The participant is in good general health according to the physician at the screening visit.  
          Exclusion criteria 
▪ Treated with medication that affects the intestinal function such as H2- blockers, inhibitors, diuretics, 
antiemetics, antidepressants, or antacids. 
 
▪ Treated with antibiotics within 3 months prior to screening (oral, parenteral or rectal), but not spray or 
ointment.  
▪ Treated with steroids within 1 month prior to screening (including oral drink). 
▪ The participant has taken any investigational drugs within one month prior to screening. 
▪ The participant has had surgery or trauma with significant blood loss or has donated blood within the last 
three months prior to the screening visit.  
▪ Diabetes type 1 or 2, or persistent high blood sugar levels. 
▪ The subject has tested positive for HIV. 
▪ HBsAg or anti-HCV positive. 
Abbreviations: BMI = body mass index, HIV = human immunodeficiency virus, HBsAg = 
Hepatitis B surface antigen, anti-HCV = hepatitis C virus antibody. 
 
2.3 COURSE OF THE INTERVENTION STUDY 
The intervention was conducted at The Western Norway University of Applied Sciences sports 
lab and divided into three phases. Phase number one consisted of physical assessment, health 
status and baseline measurements of body composition 7-14 days before the first intervention 
day. Intervention day one and two, referred to as phase two and three, were both build up in the 
same manner with the participants meeting in the fasting state at their individual assigned time 
to consume a standardized meal followed by high-intensity cycling test until exhaustion, 




2.3.1 Phase one 
On their first visit all participants were informed about the aim of the study and how the 
intervention would proceed. A written informed consent form was handed out and collected 
before further assessment was made.  
 
Screening of health status was based on self-reported questionnaires and a physical assessment 
performed by a physician. Following approved physical assessment, a maximal exercise test 
was preformed to find the lactate threshold (LT) and the estimate of the maximum oxygen 
uptake (VO2max) through a cardiopulmonary incremental exercise test (CPET). A body 
composition analysis was performed with an InBody 720 scanner (InBody Co., Ltd, Cerritos, 
California, USA) accompanied by height and weight measurements. This way all participants 
were registered with total body weight and height, FFM, FM, muscle mass (MM) and body 
mass index (BMI) before start-up. 
 
2.3.2 Phase two 
To their second visit, participants were allocated a date and time 9-16 days after phase one. The 
second phase consisted of two sessions of cycling until exhaustion with a four-hour recovery 
period in between and a diet intervention.  
 
All participants met to their given date and timeslots in the fasting state. Upon arrival 
information of the logistics and procedures of the day were carefully described. Further, a 
peripheral venous catheter (PVC) was inserted into an antecubital vein in each participant. 
Before the standardized breakfast meal was served (section 2.3.4), baseline blood samples in 
the fasting state were conducted. The participants each received a designated can to collect 
urine throughout the day. Water intake was also recorded, with a water restriction of 2.5-3.0 L 
while testing.  
 
One hour after they finished their standardized breakfast, the first exercise session began. Each 
exercise session was initiated with a 20 minutes warm-up at 60% of VO2max, followed by the 
first increase of load to reach 90% of VO2max until 5 minutes had passed, and then another 
increase of load to reach 95 % of VO2max until exhaustion. When the participant reached the 
exhausted level of both exercise session, venous blood was collected at 0, 15, 30, 60, 90, and 
120 minutes accompanied by questionnaires regarding abdominal pain, satiety, hunger, nausea, 
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desire to eat, and diarrhea (Appendix 8 and Appendix 9).  Immediately after the exhaustion 
exercise test was completed and before the blood sample at 0 minutes was collected, the 
participants each had the choice of choosing one of the intervention test drinks, A or B, without 
anyone participating in the study knowing which of the drink contained MPH. 
 
Following the blood collection at 120 minutes, a standardized heated dinner meal was 
immediately served (section 2.3.4) followed by a two-hour long recovery period before the next 
exhaustion test session, four hours of recovery all together. The next session was performed in 
the same manner as the first one, with the exception that they did not receive the intervention 
drink after the exhaustion test. When the last blood sample at 120 minutes was collected, the 
participants were free to go home.   
 
2.3.3 Phase three 
At their third and last visit, the participants met at the same time as their second visit to make 
the time of the day consistent to avoid circadian variance. They had then been through a seven-
day washout period since the last visit, phase two. Each participant was informed that they were 
going to follow the exact same procedure as their previous visit in this final phase. However, 
to complete the crossover testing of the study, each participant received the reverse intervention 
test drink of which they choose in phase two. Figure 3 shows the flow-chart with an overview 
















   TIME PHASE #2 
 
7 DAYS 
“WASH-OUT”  PHASE #3 






         




   
Rest 
45 min 







20 min 60% VO2MAX  
Warm up 
20 min 
         




 5 min 90% VO2MAX 





         




294 Kcal  Test drink 
         
 START 10:05 
Rest – 120 min 
Blood 
collection 








     
 
 












423/ 396 Kcal 
 Hot meal 
 
 
      




   
Rest 
100 min 






20 min 60% VO2MAX  
Warm up 
20 min 
        












         
   








Rest – 120 min 
Blood collection 
         
END   17:10      
         
Figure 3: Flow-chart of phase two and phase three of the intervention study. 
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2.3.4 Standardized meals  
During phase two and three of the intervention, the participants were served two standardized 
meals each with the same content at both visits. Breakfast was the first meal served right after 
information about logistics and the procedures of the day and fasting blood samples were 
collected. This was a standardized meal delivered form a local pastry shop at Kronstad, Bergen. 
The meal consisted of whole grain baguette with lettuce, pepper, cucumber, ham and cheese 
with a cup of coffee, tea or a glass of orange juice on the side by choice.  
 
The second meal was served after the last blood sample at 120 minutes past the exhaustion 
exercise. This was a heated meal with two options because one of the participants turned out to 
be a pescatarian (excluding white and red meat from their diet, but do include fish and other 
seafood). The two options turned out to be beef stroganoff (69) and cod with leek sauce (70) 
both from the same producer, Fjordland AS. An overview of the nutritional value of the 
composition in both standardized meals are shown in Table 4 excluding lettuce, pepper, 
cucumber, tea, coffee and water considering these does not contain any significant amounts of 
nutrients that would have influenced any of the important values in this study.   
 
Table 4: Nutritional content of the standardized meals given in phase two and three. 










Breakfast;      
Bread 92.6 228.0 2.0 41.9 8.0 
Ham 24.9 26.0 0.9 0.0 4.5 
Cheese 33.3 117.0 9.0 0.0 9.0 
Total: 150.7 457.0 12.3 61.1 22.9 
Orange juice 
200.0 86.0 0.4 19.2 1.4 
Hot meal;      
Beef stroganoff,      
Total: 460.0 409.0 8.3 59.8 26.7 
Cod in leek sauce,      
Total: 550.0 391.0 5.5 37.4 30.8 
Abbreviation: CHO = carbohydrate  
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2.3.5 Test drink; MPH or placebo 
In the second and third phase of the study each participant received an intervention drink after 
the first endurance cycling test was performed. They were given the free choice of choosing 
between test drink A or B in phase two. This choice then decided which drink they would be 
given in phase three, as it would be the opposite of what they had chosen in phase two (Figure 
4).  The content ratio between macronutrients were respectively the same in both drinks with 
12 E% protein, 22 E% fat, and 66 E% carbohydrate. They were both isoenergetic and 
isonitrogenous which mean that they contained the same amount of energy and nitrogen 
avoiding unnecessary variance in nitrogen intake. The energy content was measured to be 3.68 
kcal/kg BW and each intervention drink was carefully fitted to each participant to match their 
BW.  
 
Figure 4: Randomization of the intervention drinks. 
In phase two each participant chose if they wanted drink A or B, this resulted in nine 
participants choosing drink A and five drink B. They then received the opposite in phase three.  
 
One of the intervention drinks were a placebo consisting of whey protein concentrate (WPC80 
from Tine ASA, Bergen), vegetable fat (medium chained triglycerides (MCT) fat powder, 70:30 
from BERGMAST) and maltodextrins (DE 20-21) derived from corn. The other test drink was 
the MPH drink were all the main components were equal to the placebo, except for 3.2 E% of 
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the WPC protein was replaced with MPH made of fish filet from Atlantic cod. 3.2 E% equals 
about 20 mg of MPH/kg BW. 
 
 
Figure 5: Nutritional content in the intervention drinks. 
Intervention drink A: 8.8 E% WPC, 3.2 E% MPH, 22 E% MCT, and 66 E% Carbohydrates. 
Intervention drink B: 12 E% WPC, 22 E% MCT, and 66 E% Carbohydrates. 
Abbreviation: E%= energy percent, MPH= marine protein hydrolysate, WPC= whey protein 
concentrate, MCT= medium chained triglycerides.  
 
As the drinks came in powder form, the powder had to be dissolved in cold water into a creamy 
drink using the ratio of 2 ml cold water to 1 g powder. The final mix between these components 
was made approximately 30 minutes before the participants had completed their first exhaustion 
test. Both products were complemented with the technical natural flavor of strawberry and a 
light pink coloring agent to even out a potential difference in taste and smell, respectively.  
 
2.3.6 Restrictions during the study period 
A few restrictions during the intervention period was necessary. Participants were not allowed 
to drink more than five cups of coffee a day and had to avoid alcohol consumption 48 hours 
prior to each visit. Each participant was informed to abstain from exercise 24 hours prior to all 
intervention days. They were told to maintain approximately the same intensity, volume and 
frequency of their training in between phase two and three as before phase two. This was done 
to make the starting point as similar as possible. Also, as described in the exclusion criteria 
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(Table 3), medication that could affect the intestinal function was not allowed. To be able to 
control differences in dietary habits, they were all instructed and informed how to conduct a 
three-day dietary intake register before phase two and one-day dietary intake registration before 
phase three.   
 
2.3.7 Blinding  
Throughout the intervention all participants, technicians and researches were blinded to which 
content the different bottles contained until most of the statistical analyses were completed. To 
make this possible, both the intervention test drink and placebo were in identical opaque glass 
bottles marked with only the letter A or B and the participants ID when provided from the 
manufacture Firmenich Bjørge Biomarin AS (Aalesund, Norway).  
 
2.4 DATA COLLECTION  
In this study several biomarkers, anthropometric measures, dietary intake records and symptom 
questionnaires have been performed, analyzed and considered a long with physical capacity. 
Some of these collected data has been considered to be beyond the scope of this thesis and/ or 
covered by previous master students.  They will therefore not be included nor further discussed.   
 
2.4.1 Urine sampling 
At the beginning of both intervention days, each participant was handed a can an instructed 
to collect urine throughout the day, consuming only controlled amounts of protein. They were 
told to record intake of water they consumed while at the intervention, with an upper limit 
intake of 2,5-3,0 L. At the end of both test days we were left with one can from each participant. 
The urine in each can was measured, stirred and sampled into a smaller can measuring only 100 
ml for storage at – 20 oC until further analysis.  
 
2.4.1.1 Nitrogen 
To measure the amount of excreted nitrogen in the urine, the Kjeldahl method was performed 
by Nofima AS (Bergen, Norway) (71) 
The nitrogen level is determined by the following principle: 
1. The sample is dissolved by concentrated sulfuric acid using copper as a catalyst. The 
nitrogen in the protein gets reduced and converted to ammonium sulfate.  




First step, weighing, involved transferring 1 gram of each sample to a tube made of glass 
whereas two catalyst tablets, 15.0 ml concentrated H2SO4 were added. The complete solution 
was dissolved using the following temperature program; 
1. Gradually heating to 420 °C during approximately 1 hour.  
2. Keep the temperature at 420 °C for 2 hours and 20 minutes. 
3. Cool down the sample.  
 
Second step, distillation, separate tubes were filled with distillation fluid, indicator solution, 
titration acid and distilled water at the distillation unit. The distillation unit automatically adds 
all solutions by titrating until the dark-colored medium has become clear and colorless.  
 
Each time batch number on indicator solution, titration acid was changed, or a different 
equipment, chemicals or environment was used, blank test samples had to be performed with 8 
blanks and calculations of the average result. The blank value was then deducted from new 
results.  
 
Estimated intake of nitrogen was calculated by dividing protein intake by 6.25 which is the 
estimated factor of nitrogen in protein. Nitrogen values were measured by analyzing total urine 
collected at both intervention days and validated against the controlled protein intake to 
estimate a measure of nitrogen metabolized. Estimated intake of nitrogen was 9.16g for all 
participants. 
  
2.4.1.2 1-Methylhistidine, 3-Methylhistidine and creatinine 
To measure the levels of 1-MH, 3-MH and creatinine in urine, the liquid chromatography 
tandem mass spectrometry (LC-MS/MS) method in platform C was performed by Bevital AS 
(40). The level of the different parameters is determined by the following principle; a detection 
method that relies on the mass-to-charge ratio of a compound. The method used by Bevital AS 
is published in this article (72).  
 
2.4.2 Blood sampling 
During intervention days phase two and three, blood collection was performed through a PVC 
(infusion cannula 18G, BD) in the antecubital vein. The blood was conducted by a qualified 
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nurse and the catheter was washed with 2.5 ml saline solution prior to each blood sampling and 
a 3-way tap was used. The first sample was taken at baseline in the fasting state upon arrival 
followed by intervals of 0, 15, 30, 60, 90, and 120 minutes after completion of each exhausting 
exercise session.  
Included in this thesis, data collection in blood was limited to baseline measures upon arrival 
and 0- and 60-min samples after the second exhaustion excise session. These measures were of 
the most relevance to the scope and purpose of the selected biomarkers focused on in this thesis. 
This resulted in six different blood samples from each participant, three from each intervention 
day with either the consumption of test drink A or test drink B to be able to compare the two. 
Under the scope of this thesis, CK, 1-MH, 3-MH, creatinine and RBP4 are the blood biomarkers 
included in analysis and will be further discussed.  
Serum 
Handling of blood samples to be separated into clean and stable serum samples was performed 
by filling up serum gel tubes (Vacuette® Ref 454067R, Greiner Bio-One) and mix the content 
by turning the tube a few times and left in room temperature for about 30 minutes. The 
separation of serum from clotting factors in blood were performed by centrifugation at 2000 G 
for 10 minutes. The serum had now been separated as an upper layer in the tube, which could 
easily be transferred by pipetting into new sterile cryotubes marked with the participants ID 
and coding of sample.  
 
Serum samples collected and prepared were stored at -20 °C until all samples were collected 
from all participants each intervention day. At the end of the day samples were transported on 
ice to Haukeland University Hospital to be stored at -80°C until laboratory tests were ready to 
be conducted. Relevant for this thesis, CK was the biomarker analyzed in serum.  
 
2.4.2.1 Creatine kinase 
Measuring the levels of CK in serum, photometry was used as the method to detection by the 
Laboratory of Clinical Biochemestry (Labaratorieklinikken) at Haukeland University Hospital 
(73). 
 
The level of CK is determined by the following principle; quantity measurement of light 
absorbing analyte in a sample. The exposure of incident light leads to absorption in analytes 
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which then will reflect light at a lower intensity. The color of the samples is defined by light 




Handling of blood samples to be separated into clean and stable plasma samples was performed 
by filling up, prepared ethylenediaminetetraacetic acid tubes (EDTA-tubes Vacuette® Ref 
G454047, Greiner Bio-One) added dipeptidyl peptidase-4 (DPP-4) inhibitor. This inhibitor was 
not necessary for the analysis preformed in this thesis, but the same plasma was used to analyze 
Glucagon-like peptide-1 by another master student which required this inhibitor. The content 
was mixed by turning the tubes a few times followed by centrifugation at 1800 G at 4°C for 10 
minutes within 20 minutes of collection. The plasma was then separated from white blood cells, 
platelets and red blood cells which was pipetted and transferred to sterile cryotubes labeled with 
the participants ID and coding of sample.  
 
Plasma samples collected and prepared were stored at -20 °C until all samples were collected 
from all participants each intervention day. At the end of the day, samples were transported on 
ice to Haukeland University Hospital to be stored at -80°C until laboratory tests were ready to 
be conducted. Relevant for this thesis 1-MH, 3-MH, creatinine and RBP4 were the biomarkers 
analyzed in plasma. 
 
2.4.2.2 1-Methylhistidine, 3-Methylhistidine and creatinine 
To measure the levels of 1-MH, 3-MH and creatinine in plasma, the LC-MS/MS method in 
platform C was performed by Bevital AS (40). The level of the different parameters is 
determined by the following principle; a detection method that relies on the mass-to-charge 
ratio of a compound. The method used by Bevital is published in this article (72). 
 
2.4.2.3 Retinol-binding protein 4  
The collection method used to measure RBP4 was an enzyme-linked immunosorbent assay 
(ELISA) kit by Immundiagnostik AG (Bensheim, Germany, REF K6110). This two-sided 
“sandwich” technique is intended for the quantitative determination of free RBP4 as well as 
RBP4 complexed with transthyretin in plasma. The kit was stored at -4°C, while plasma 
samples were taken out form the freezer at - 80°C approximately one hour before use. Included 
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in the kit there were a 96 well microtiter plate (pre-coated), ELISA wash buffer concentrate, 
sample dilution buffer, conjugate concentrate (CONJ, rabbit anti RBP/RBP4, peroxidase), 2x5 
lyophilized standards (STD), two lyophilized controls (CTRL), tetramethylbenzidine substrate 
(TMB), and ELISA stop solution.  
 
Preparation of reagents 
The wash buffer concentrate was diluted with ultra-pure water 1:10 before use. The lyophilized 
STD and CTRL were reconstituted with 500 ul of ultra-pure water and allowed to dissolve for 
10 minutes and mixed thoroughly to ensure complete reconstitution. Before use, also the CONJ 
was diluted to 1:101 in wash buffer. All other test reagents were ready-to-use.  
 
Preparation of samples 
All samples were diluted with sample dilution buffer (SAMPLEBUF) until 1:5 000 before use, 
this was done in three steps: 
- 20 ul sample + 980 ul SAMPLEBUF = 1: 50 (dilution I) 
- 5   ul dilution I + 45 ul SAMPLEBUF = 1: 10 (dilution II) 
- 10 ul dilution II + 90 ul SAMPLEBUF = 1:10 (dilution III) 
This resulted in a final dilution of 1: 5 000. The last dilution was made directly into the well on 
the 96-microtiter plate. 
Assay procedure 
All reagents and samples were brought to room temperature (15-30°C) and vortexed. The 
protocol sheet with positions of standards/controls/samples are showed in Appendix 7. In total 
there was 2x5 STD, two controls and 84 samples. Samples were marked with the given 
participant identification and coding. The coding consisted of the letter A which represented 
baseline samples taken in the fasting state upon arrival the first intervention day, while D 
represented the same sample the second intervention day. The letter C0 represented the blood 
sample taken 0 min after the second exhaustive endurance cycling test equal to 5 hours after 
the test drink the first day (7hours after baseline) and F0 the second day, while C3 or F3 
represented the same only 60 minutes after the second exhaustive endurance cycling test equal 
to 6 hours post the test drink (8hours after baseline).  
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To start of the procedure, the wells were washed thoroughly 5 times with 250 ul wash buffer. 
Following, 100 ul STD/CTRL/ diluted samples were added to the wells. As mentioned above, 
the last dilution of the sample was made directly on the plate. The plate was then covered and 
incubated for 1hour at room temperature on a horizontal shaker. The contents were then 
discarded, and the plate washed with wash buffer, before 100 ul CONJ was added, covered and 
again incubated for 1hour at room temperature and on a horizontal shaker. The contents were 
again discarded, and the plate washed five times. To develop readable absorbance 100 ul TMB 
substrate was added followed by an 10-20 minutes incubation in room temperature, but this 
time covered by a foil cap to create a dark environment. After this incubation 100 ul ELISA 
stop solution was added and vortexed.  
The absorption was immediately determined with an ELISA reader (spectra max plus, 
microplate spectrophotometer) with a wavelength at 405 nm against 650 nm as a reference.  
 
Figure 6: The principle of RBP4 sandwich ELISA method. 
In the first incubation step, RBP4 in the samples are bound to polyclonal rabbit anti RBP4 
antibodies, immobilized on the microtiter plate. A peroxidase-conjugated anti RBP4 antibody 
is used for detection and quantification, and tetramethylbenzidine (TMB) as a peroxidase 
substrate. A dose-response curve of absorbance unit (optical density at 405 nm) vs. 
concentration is generated using the values obtained from standard. RBP4 present in the 










2.5 DATA ANALYSIS AND STATISTICS 
All data analysis and statistics were performed using Microsoft Excel © 2019 for Mac 
(Microsoft Corporation, Redmond, WA, USA) and IBM SPSS Statistics for Windows Version 
25.0 (IBM Corp. Armonk, NY). All figures are presented based on median values with a 
percentile of 0.25 as recommended by a statistician.  
 
A descriptive analysis of each participant demographics measured with InBody 720 scanner 
(InBody Co., Ltd, Cerritos, California, USA) during phase one is presented as mean, SD (±), 
95% CI (lower, upper), and range (min, max) values.  
 
Estimated intake of nitrogen was calculated by dividing protein intake by 6.25 which is the 
estimated factor of nitrogen in protein. Concentration results of nitrogen in the urine analysis 
performed by Nofirma AS, was converted to gram by calculating the analyte amount in total 
urine excretion from each participant (1 % N = 10g N / L urine). Nitrogen intake and the analyte 
level estimated in the urine from each participant was then used to calculated retained nitrogen. 
Results are presented with a bar graph based on median values with 0.25 percentile. 
 
1-MH, 3-MH and creatinine in urine were analyzed using IBM SPSS and are presented as mean 
values with 95% confidence interval (CI). 1-MH, 1-MH/ 3-MH, and 3-MH/ Creatinine were 
not normally distributed, so a non-parametric Wilcoxon singed rank test had to be used. 
Considering there are more than one dependent variable in the ratio, measures in urine were 
also controlled for multiple testing with the one-way multivariate analysis of variance (one-way 
MANOVA).  
 
To analyze CK, 1-MH/ 3-MH, 3-MH/ Creatinine, and RBP4 levels with respect to time and 
drink, a mixed linear model was used assuming a compound symmetry correlation structure 
between measurements from the same test person, and testing interactions between the 
predictors. Results are presented as F-tests with degrees of freedom, p-values accepted as 
significant with p-value of or below 0.05, and estimated regression coefficients with 95% CI. 
The Shapiro-Wilk normality test was used to test for normal distribution.  
 
A Spearman’s rho non-parametric correlation was performed to examine possible associations 
between the biomarkers analyzed. 
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2.6 ETHICS STATEMENT 
This intervention was conducted according to the guidelines in the declaration of Helsinki. The 
policy covers how each potential participant to be included in the intervention shall be informed 
about the intervention, aim, procedures, favourable and unfavourable effects. It also includes 
the right to participate and the right to withdraw their consent without any justification, and 
how the participant information will be handled. All potential participants were carefully 
informed both oral and written about each point of this policy before the written informed 
consent had to be fully understood, signed and handed in prior to inclusion of the study.  
 
The study is approved by the Western Norway Regional Committee for Medical and Health 
Research Ethics (REK 2017/56) of all procedures concerning involvement of human subjects. 
An ergometer commonly used to determine exercise capacity was used during the endurance 
exercise test. Considering how this was a strenuous test performance, a physician was present 
during every phase of the study to lead the safety assessment during every endurance test. The 
wellbeing of each participant was always prioritized. Any sign of discomfort immediately led 
to ending of the test preformed.   
 
All personal information collected from each participant was handled with complete 
confidentiality. Each participant received a personal identification number at their first visit. 
This was a necessity to sort the data collection and reporting from each participant at every visit 
and make all samples anonymous throughout the rest of the intervention. All collected data 
were stored without any identifiable information and with password protection. In addition, 







3.1 DEMOGRAPHIC OF THE PARTICIPANTS  
The total of 14 healthy male participants recruited conducted the study. Their self-reported 
lifestyle before and in between intervention days focusing on dietary habits and physical 
activity did not show any remarkable difference. However, there was one exception where 
heavy physical work in a job context 1-2 days before the last intervention day had been 
performed. Analysis results influenced by this were excluded in further analysis covered in this 
section. Regarding all figures included in this section, the two drinks will be separated by color. 
Blue will be representing the MPH drink, while grey will be representing the placebo drink. 
 
Detailed baseline demographics of the study population are listed in Table 5. The average age 
of the participants was 46 years with a range from 40 to 58. Measured mean height was 180.8 
cm (SD ± 4.1), weight 80.1 kg (SD ± 6.4), and a BMI of 24.5 kg/m2 (SD ± 2.2). Further inbody 
anthropometric measures preformed with BIA showed an FFM of 66.6 kg (SD ± 3.7), FM of 
13.5 kg (SD ± 4.5, 16.6%, SD ± 4.4), and MM of 37.7 kg (SD ± 2.3).   
 
Table 5: Demographics of the participants in phase one, n=14. 
Abbreviations: BMI=body mass index, FFM=fat free mass, FM=fat mass, MM=muscle mass, 
SD=standard deviation, CI= confidence interval.  
Characteristics Mean SD (±) 95% CI (lower, upper) Range (min, max) 
Age (years) 46 5 43, 49 40, 58 
Height (cm) 180.8 4.1 178.4, 183.2 176.0, 192.0 
Weight (kg) 80.1 6.4 76.4, 83.8 71.2, 96,2 
BMI (kg/m2) 24.5 2.2 23.3, 25.8 21.4, 29.4 
FFM (kg) 66.6 3.7 64.5, 68.7 60.4, 71.5 
FM (kg) 13.5 4.5 10.9, 16.1 5.8, 24.7 
FM (%) 16.6 4.4 14.4, 19.1 7.8, 25.7 
MM (kg) 37.7 2.3 36.4, 39.0 33.9, 40.9 
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3.2 URINE ANALYSIS 
Total urine was collected and registered during a period of about 9hours while the participants 
were present in phase two and three. Registered amount of urine was later used to estimate the 
analyte level in total urine with the analysis results from both Nofima AS and Bevital AS. All 
urine results are presented as analyte level in total collected urine. Urine samples from 
participant 13 were not collected at neither of the intervention days. Amount of collected urine 
was not registered from participant 14 after consuming MPH, making it difficult to calculate 
the analyte level resulting in the exclusion of nitrogen metabolized in this measure.  
 
3.2.1 Nitrogen   
To calculate the nitrogen balance, the controlled and estimated nitrogen amount of 9.16 g in 
consumed intake during the intervention day in each participant was used. The analyte level of 
nitrogen in the total urine was calculated by converting % N to g/L (1% N = 10 g/L) and 
multiplied with total amount of urine (L) collected in each participant. Results are presented in 
Figure 7 which compare the two drinks according to intake, nitrogen metabolized, and 
calculated nitrogen retained in the body.  
 
The analysis result following the MPH drink showed that nitrogen metabolized was 
significantly lower (p < 0.001) from the controlled nitrogen intake, as well in the placebo drink 
(p = 0.001). Nitrogen analysis regarding the intake of MPH showed a slightly lower level of 
metabolized nitrogen of 5.91 g compared to the nitrogen level metabolized of 7.42 g following 
the placebo drink. However, results show no significant difference in nitrogen levels 
metabolized between the two intervention drinks with a p-value of 0.315. 
 
Retained nitrogen was calculated to be 3.25 g following the MPH drink and 1.74 g following 






Figure 7: Nitrogen intake, metabolized and retained after consuming MPH or placebo drink. 
Nitrogen intake estimated from controlled intake throughout the day. Nitrogen metabolized 
were measured in urine samples after intake of MPH over a 9hour period in each participant. 
Retained nitrogen was calculated by using the intake measure and metabolized levels of 







































3.2.2 1-Methylhistidine, 3-Methylhistidine and creatinine 
In the analysis of 1-MH, 3-MH and creatinine, several values were missing leaving only n= 13 
for mean measures, and n=9 participants in calculations of the ratios see Table 6. 1-MH did not 
fulfill the requirement of a normal distribution, so a non-parametric Wilcoxon signed rank test 
had to be used. Results showed that neither of the biomarkers are significantly different. 1-MH 
was mainly analyzed to get the true measure of 3-MH by the ratio 1-MH/ 3-MH since the 
participants did not eat a meat-free diet before testing. Thus, 1-MH/ 3-MH ratio will be used as 
the relevant measure further. This ratio showed a significant difference with p-value at 0.028 
between the two drinks. However, with the correction of the one-way MANOVA, the 1-MH/ 
3-MH ratio did not show a significant difference (p = 0.107).  
 
Table 6: 1-MH, 3-MH and creatinine measures from urine, n= 131. 
Parameter Mean 95% CI (lower, upper) P-value* MANOVA 
1-MH 1,3 350.90 208.01, 493.79 0.110  
3-MH 1 231.67 204.16, 259.18 0.815  
Creatinine 1 7.41 6.65, 8.16 0.686  
1-MH/ 3-MH2,3 1.53 0.84, 2.23 0.028* 0.107 
3MH4/ Creatinine2,3 0.24 0.10, 0.38 0.066 0.121 
     *Statistical accepting P < 0.05 as significant. 
1Missing values from participant 13.  
2Missing value from participant 1,2,3, 13, and 14 in ratio 1-MH/ 3-MH, and 3-MH/ Creatinine. 
3Was not normally distributed, therefore a non-parametric related-samples Wilcoxon Signed 









Figure 8 displays calculations of the 1-MH/ 3-MH ratio from both drinks in urine based on 
median values with a percentile of 0.25. The bar graph shows how the MPH test drink resulted 
in a higher ratio than the calculated ratio following the placebo test drink. Despite this, the one-
way MANOVA gave no significant difference between the two drinks (p = 0.107). 
 
 
Figure 8: 1-MH/ 3-MH ratio from both MPH and placebo drink. 
Calculated ratio from 1-MH and 3-MH measured in urine following either MPH or placebo 
test drink collected over a 9hour period in each participant. Values are listened as median 
























1-MH/ 3-MH  
46 
 
Figure 9 displays calculations of the 3-MH and creatinine ratio, where 3-MH is the true value 
representing the 1-MH/ 3-MH ratio, from both drinks in collected urine. Opposite to the 1-MH/ 
3-MH ratio, this bar graph shows a lower ratio following the MPH test drink, and a higher ratio 
following the placebo test drink, but there was no significant difference (p = 0.121). 
 
 
Figure 9: 3-MH/ Creatinine ratio from both MPH and placebo drink. 
Calculated ratio from 3-MH (1-MH/ 3-MH) and creatinine measured in urine following either 
MPH or placebo test drink collected over a 9hour period in each participant. Values are 


























3.3 BLOOD ANALYSIS 
Blood samples included in all analysis are collected from baseline, 7hours and 8 hours post 
baseline. Baseline is in the fasting state upon arrival while 7hours and 8hours are equal to 0- 
and 60 min post second exhaustion endurance cycling session. The same measures are used at 
both intervention days to be able to use each participant as their own control. A mixed linear 
regression analysis was conducted for all biomarkers in this section. This type of analysis will 
consider differences between the two drinks combined in relation to the independent variables 
time (baseline, 7h, 8h) and drink (MPH or placebo). Regarding line charts displayed in Figure 
10, 11, 12 and 13, between the two first time measures, time elapse over a 7hour period 
displayed with a non-continuous line. Between the second- and third-time measure, time elapse 
over a 1hour period displayed with a continuous line.   
 
3.3.1 Creatine Kinase 
Participant 12 was excluded from the analysis because of measurements following high 
physical demand related to work only a couple days before testing resulted in false measures. 
The analysis resulted in no significant difference between drinks (p = 0.823), but there was a 
significant difference between time measures (p < 0.001). Results are listed in Table 7. 
 
Table 7: Estimates of fixed effects1 CK analysis in serum n=132.   
Parameter1  Estimate 95% CI (lower, upper) F P-value* 
Intercept 4.74 4.55, 4.92 5256.15 < 0.001* 
Time    42.57 < 0.001* 
Baseline 0.003 0.003   
7h 0.20 0.11, 0.29   




Placebo 0.003 0.003  
 
MPH 0.03 -0.16, 0.22  
 
Time x Drink 
  
0.87 0.441 
Baseline x MPH 0.003 0.003  
 
7h x MPH 0.00 -0.12, 0.12  
 




*Statistical significance was evaluated using two-sided pair wise t-test accepting P < 0.05 as 
significant. 
1Dependent variable: lnCKserum 
2 Value from participant 12 excluded, outlier.  
3Referance 
Abbreviation: CI = confidence interval, F = fishers test, h = hours. 
 
Figure 10 display changes in CK levels in the blood with median measures and percentile 0.25. 
Both drinks follow the same curve with a slight increase after 7hours followed by a small 
decrease 1hour later. Although the MPH drink seemed to have increased a little more than 
placebo, mixed model analysis did not show any significant difference between the two drinks 




Figure 10: Serum levels of CK measured following both the MPH and placebo drink. 
7h represent 0 min and 8h represent 60 min post second exhaustion endurance cycling session, 
without participant 12 from baseline. The non-continuous line represents a 7hour period, while 
the continuous line represents a 1hour period. Values are listened as median values with a 
percentile of 0.25. 
 
Baseline 7h 8h
MPH 113 142 125













3.3.2 1-Methylhistidine, 3-Mmethylhystedine and creatinine  
Presented in Table 8 are median measures and percentile 0.25 of 1-MH, 3-MH and creatinine 
from all three-time measures after both drinks. Neither of the values between drinks are 
significant. On the other side, all measures seemed to have increased between baseline and 
measure point 7h, while they decreased 1hour later. As the ratio 1-MH/ 3-MH ratio are a more 
true value of 3-MH secreted in human muscle, this ratio will be preferred to use in further 
analysis. 
 
Table 8: Median 1-MH, 3-MH and creatinine measures from plasma at baseline, 7- and 8 hours 
post baseline equal to 0 – and 60 min post second exhaustion endurance cycling session. 
 MPH Placebo  
Variable  Median Percentile1 Median Percentile1 P-value2 
1-MH      
Baseline 3.70 2.26 5.26 2.11 0.794 
7h 4.31 3.63 5.50 2.78 0.467 
8h 4.21 3.23 5.18 2.89 0.536 
3-MH      
Baseline 4.29 3.85 5.22 4.39 0.128 
7h 6.22 5.15 5.90 5.13 0.723 
8h 5.81 5.48 5.78 5.64 0.719 
Creatinine      
Baseline 80.35 72.43 79.40 76.25 0.625 
7h 100.00 91.13 93.65 89.23 0.175 
8h 92.40 90.10 90.85 88.93 0.131 
1Percentile 0.25 
2Mixed linear regression analysis 
Abbreviation: MPH = marine protein hydrolysate, 1-MH = 1-Methylhistidine, 3-MH = 3-









Results from the 1-MH/ 3-MH analysis are listed in Table 9. The analysis resulted in no 
significant difference between drinks (p = 0.595), but there was a significant difference between 
time measures (p = 0.006).  
 
Table 9: Estimates of fixed effects1 1-MH/ 3-MH analysis in plasma n=14. 
Parameter1  Estimate 95% CI (lower, upper) F P-value* 
Intercept 0.03 -0.55, 0.61 0.03 0.861 
Time    7.80 0.006* 
Baseline 0.002 0.002   
7h -0.08 -0.43, 0.26   




Placebo 0.002 0.002  
 
MPH 0.07 -0.57, 0.70  
 
Time x Drink 
  
1.13 0.352 
Baseline x MPH 0.002 0.002  
 
7h x MPH 0.13 -0.08, 0.33  
 
8h x MPH 0.11 -0.09, 0.30  
 
*Statistical significance was evaluated using two-sided pair wise t-test accepting P < 0.05 as 
significant. 
1Dependent variable: ln1-MH3-MHratio 
2Referance 











Figure 11 displays changes in 1-MH/ 3-MH levels in the blood with median measures and 
percentile 0.25. Both drinks follow the same decreasing curve between measures. There was 




Figure 11: Plasma levels of 1-MH/ 3-MH ratio measured following both the MPH and the 
placebo drink. 
7h represent 0 min and 8h represent 60 min post second exhaustion endurance cycling session. 
The non-continuous line represents a 7hour period, while the continuous line represents a 











MPH 1,02 0,82 0,75















Results from the 3-MH/ Creatinine analysis are listed in Table 10. 3-MH represent the true 
value, the ratio between 1-MH/ 3-MH. The analysis resulted in no significant difference 
between drinks (p = 0.662).  
 
Table 10: Estimates of fixed effects1 3-MH2/ Creatinine analysis in plasma n=14. 
Parameter1  Estimate 95% CI (lower, upper) F P-value* 
Intercept -4.35 -4.91, -3.78 732.53 < 0.001* 
Time    1.74  
Baseline 0.003 0.003  0.215 
7h -0.25 -0.61, 0.12   




Placebo 0.003 0.003  
 
MPH 0.08 -0.55, 0.71  
 
Time x Drink 
  
0.32 0.731 
Baseline x MPH 0.003 0.003  
 
7h x MPH 0.06 -0.15, 0.26  
 
8h x MPH 0.08 -0.13, 0.28  
 
*Statistical significance was evaluated using two-sided pair wise t-test accepting P < 0.05 as 
significant. 
1Dependent variable: ln3-MHCreatininratio 
21-MH/ 3-MH 
3Referance 












Figure 12 displays changes in 3-MH/ Creatinine levels in the blood with median measures and 
percentile 0.25. Both drinks follow the same decreasing curve between the first and second 
measure, while it evens out between the second and third measure. There was no significant 
difference between the two drinks (p=0.662).  
 
 
Figure 12: Plasma levels of 3-MH/ Creatinine ratio measured following both the MPH and the 
placebo drink. 
7h represent 0 min and 8h represent 60 min post second exhaustion endurance cycling session. 
The non-continuous line represents a 7hour period, while the continuous line represents a 












MPH 0,013 0,009 0,007
















3.3.3 Retinol-binding protein 4 
The ELISA technique resulted in several measures outside the reference range. Values outside 
the reference range were all set to 0.06 during analysis of the results. RBP4 results were 
analyzed following a linear mixed regression analysis with respect to the independent variables 
time and drink all presented in Table 11. The analysis resulted in an almost significant 
difference between the two drinks with a p-value of 0.052.  
 
Table 11: Mixed model RBP41 analysis in plasma n=14.   
Parameter1  Estimate 95% CI (lower, upper) F P-value* 
Intercept 16.37 8.36, 24.39 51.12 < 0.001 
Time    1.13 0.353 
Baseline 0.002 0.002   
7h 4.17 -2.36, 10.70   




Placebo 0.002 0.002  
 
MPH -1.28 -8.70, 6.13  
 
Time x Drink 
  
0.74 0.497 
Baseline x MPH 0.002 0.002  
 
7h x MPH -3.77 -11.30, 3.77  
 
8h x MPH -5.84 -17.94, 6.26  
 
*Statistical significance was evaluated using two-sided pair wise t-test accepting P < 0.05 as 
significant. 
1Dependent variable: RBP4 
2Referance 











Figure 13 displays changes in RBP4 levels in the blood with median measures and percentile 
0.25. Both drinks have close to the same baseline measure with a median of 16.0 mg/L post 
MPH and 15.2 mg/L in placebo. The second measure showed decreasing levels of RBP4 
following the MPH drink (median:14.8 mg/L) while it increases following placebo (median: 
21.7 mg/L). Between the second and third measure, MPH seemed to have decreased to a level 
far below baseline. Placebo also seemed to have decreased between the second and third 
measure, but still at a level above baseline measure. The analysis did not show any significant 




Figure 13: Plasma levels of RBP4 measured following both the MPH and placebo drink. 
7h represent 0 min and 8h represent 60 min post second exhaustion endurance cycling session. 
The non-continuous line represents a 7hour period, while the continuous line represents a 
1hour period. Values are listened as median values with a percentile of 0.25. 
 
3.4 CORRELATIONS 
To evaluate the relationship between nitrogen balance, CK, 3-MH and RBP4 a Spearman’s rho 
nonparametric correlation was performed. Neither of the analysis gave any significant results 
and the inclusion of results were therefore considered to be superfluous in this thesis but are 
included in the Appendix 6.    
Baseline 7h 8h
MPH 16,0 14,8 7,4














This is likely the first study to examine the influence of MPH from Atlantic cod on muscle 
synthesis and degradation post exhaustive endurance cycling. This thesis suggests that a single 
dose (20 mg/kg BW) of MPH will have an impact on biomarkers related to muscle synthesis 
and degradation in addition to the superior whey protein. The main findings in this study is that 
supplementation with a single dose of MPH in addition to whey protein did not show any 
significant difference between supplementation with only whey protein on increasing muscle 
synthesis and decreasing muscle degradation. However, several biomarkers did indicate some 
differences between MPH and whey protein in favour of MPH.  
 
The discussion is divided into three sections. In the first section the main findings of this study 
are discussed, and results are compared to related studies. In the second section, strengths and 
limitations of the recruitment and participants, study design, method, urine and blood sampling 
and biomarkers are discussed. The third section do concern an evaluation of the requirement 
for further research on MPH.  
 
4.1 DISCUSSION OF FINDINGS 
4.1.1 Nitrogen balance  
Controlled intake of protein and measurements of nitrogen excreted in urine, gives us an 
estimate of how much protein was retained in the body. The urine analysis of nitrogen 
metabolized following the MPH drink showed a significant (p < 0.001) lower level of 
metabolized nitrogen from the nitrogen intake. This indicates a positive nitrogen balance where 
muscle synthesis is stimulated, and degradation suppressed. Increased muscle synthesis 
contributes to a faster restitution period post exercise and increase muscle strength related to 
better prognosis during chronic diseases (3, 21, 75). However, analysis of urine following the 
placebo drink also showed a significant difference between intake and metabolized nitrogen (p 
= 0.001). This indicates that both intervention drinks have had a positive influence on nitrogen 
balance in this study population, which could be explained by the fact that both drinks consisted 
of high-quality protein consumed at the right time. 
 
No significant difference was found when comparing the two drinks (p = 0.315). On the other 
hand, analysis does indicate a slight difference in favor of MPH as in most participants (n= 
8/12) nitrogen metabolized was higher following the placebo drink. In other words, more 
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protein was retained and available for muscle syntehsis in the body following the MPH drink. 
A study performed by Paullain M.G. et.al showed a significant difference in both retention and 
excretion of nitrogen between whole protein and protein hydrolysates in rats (55). Another 
study by Hays N.P. et.al also found a significant difference in lean body mass and nitrogen 
excretion in elderly women following intake of whey protein versus protein hydrolysate (56). 
With this to consider, there is reason to believe that if the study had included a larger number 
of participants and a better representation of the general population, results might have shown 
the two drinks to be significantly different.   
 
4.1.2 1-Methylhistidine/ 3-Methylhistidine and 3-Methylhistidine/ Creatinine 
The metabolized nitrogen in urine reflects the impact on nitrogen balance but indicate only net 
protein breakdown. Measurement of 3-MH in the urine enables the estimated contribution of 
increased muscle catabolism to the negative nitrogen balance associated with muscle wasting 
and nitrogen loss (41). Analysis on urine showed no significant differences between drinks 
concerning these biomarkers. This might be explained by the fact that the collection period of 
urine was too short to see any differences as these biomarkers usually peak 12 to 24 hours after 
exercise. Even though there was no significant difference, the 1-MH/3-MH ratio seemed higher 
in the MPH group, indicating that excretion of 3-MH from degenerating muscle was reduced. 
Supporting this, the 3-MH/ Creatinine ratio was measured to be lower following the MPH drink 
compared to the placebo drink.  
 
Considering that the collection period of urine is such a limiting factor, measurements of 1-
MH, 3-MH, and creatinine was also analyzed in blood to support our results. Like Paul G.L. e.t 
a.l found out (76), all three biomarkers seemed to have slightly increased 0 min after the second 
exercise session, while they decreased again only 1hour later following both drinks. The fact 
that these biomarkers seemed to have increased then decreased could indicate that the protein 
degradation began during exercise, but then stopped as the physical demand slowed down and 
sufficient protein was available for synthesis. On the other side, this increase in the single 
biomarkers might be explained by the meat containing meal they were served during both 
intervention days, between baseline and the second measure. Supporting this, results of the 




In addition to that the excretion of 3-MH in healthy individuals are proportional to the fat free 
body mass, creatinine serves as a useful measure as it is produced in the skeletal muscle (77). 
The more skeletal muscle a person has, the more creatinine will be excreted. Expressing 3-MH 
relative to creatinine helps to account for possible changes in kidney functions that may occur 
during and post exercise (39). The ratio 3-MH/ Creatinine has been proposed as an indicator of 
fractional muscle protein breakdown (77).  
 
Both results showed decreased levels of the ratios which might be explained by that fact that 
during exhaustive endurance cycling, there was a temporary failure of protein synthesis, rather 
than an increase in muscle degradation. This theory is supported by Carter E.M. et.al. (41), 
which states that identifying the catabolic contribution to overall protein loss may show that in 
other muscle wasting conditions failure of protein synthesis should be a more important focus 
than muscle degradation (41). 
 
Results from the linear mixed regression analysis showed no significant difference between the 
two drinks considering the 1-MH/ 3-MH ratio. It did however show a significant difference 
between time which means that the levels did significantly change between measures (p = 
0.006). It was no significant difference between the 3-MH/ Creatinine ratio in the two drinks. 
Similarity between the urine and plasma results are that the 1-MH/ 3-MH ratio was still higher 
following the MPH drink. Further, the 3-MH/ Creatinine ratio did not support the higher 1-MH/ 
3-MH result in plasma like it did in urine, as the 3-MH/ Creatinine turned out to be higher 
following the MPH drink than the placebo drink in plasma.  
 
4.1.3 Creatine kinase 
The linear mixed regression analysis of CK serum revealed no significant difference between 
the two drinks (p = 0.823). Considering CK serum levels are measured to peak 24 hours after 
exercise by previous studies (36, 76), a longer measurement period could be necessary to 
discover differences between the two drinks.  
 
The analysis revealed a highly significant difference between time (p < 0.001), whereas CK 
levels have changed significantly between time measures indicating an early increase in CK 
levels. In addition, this study chose to only focus on a few measurements where there was a 
7hour period between the two first measures and a 1hour period between the second- and third 
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measure. In between the two first measures, two alike exhaustive excise sessions had been 
performed. Considering other studies have shown how CK easily adopt to similar high physical 
demand, higher CK levels may have occurred following the first exercise session (78, 79).  
 
Results show that between baseline and the second measure, CK levels rise. This indicates that 
right after exercise, CK measures increase. The MPH drink seemed to have caused a slightly 
more increased CK level than the placebo drink. However, the restitution period between the 
two exercise sessions could have been too short which gave increased CK levels at the second 
measure, before it decreased at the third measure for both drinks to a level right above baseline 
level. Another possible explanation of the decreased CK level between the second- and third 
measure could be due to an acute phase response where muscle degenerate quickly right after 
exercise but slows down as the muscles cool down.  
 
Analysis regarding time x drink did not find any significant difference (p = 0.441), which again 
could be explained by the short measurement period mentioned above. Considering that others 
have looked at measurements up to 48 hours post exercise, a longer time measure would be 
relevant (76, 80). Another theory is that both drinks consisted of the same amount of high-
quality protein which was already in the body at the second- and third measure and did not 
differ enough in its capability to increase muscle synthesis and/or decrease muscle degradation.   
 
4.1.4 Retinol-binding protein 4 
Blood analysis preformed with a linear mixed regression analysis showed no significant 
difference between time measurements (p = 0.353). The analysis showed an almost significant 
difference between drinks with a p-value of 0.052, although time x drink did not show any 
significance (p= 0.497). The almost significant measure in drink indicates that the protein pool 
in the body could have been significantly different between the two drinks if more participants 
and a higher dose of MPH was used. RBP4 has a half-life of 12hours which means that a longer 
measurement period would not have been very beneficial in this biomarker (46, 49).  
 
Interestingly, between baseline and the second measure, RBP4 levels raised following the 
placebo drink while RBP4 decreased following the MPH drink. One theory is that this happened 
because more of the protein was already absorbed into the muscle following the MPH drink. 
This theory is supported by the fact that the nitrogen metabolized also indicated a lower level 
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of nitrogen metabolized in the MPH drink than the placebo. Between the second and third 
measure, both drinks showed a decreased level of RBP4 in the blood. The placebo measure 
stayed at a level above baseline, while the MPH seem to have dropped at a higher rate and 
decreased below baseline. As the RBP4 levels is said to be a measure of the total protein pool 
in the body (49), this suggest that more protein was absorbed into the muscle and available for 
muscle synthesis following the MPH drink compared to the placebo drink.  
 
4.2 STUDY STRENGTHS AND LIMITATIONS 
This study had several strengths and limitations, some which are discussed beneath divided into 
recruitment and participants, study design, method, urine and blood sampling and biomarkers.  
 
4.2.1 Recruitment and participants 
This study to focused on a narrow group of the population; healthy male, medium trained with 
a total amount of 8 to 12 hours weekly training and cycling as their main exercise activity. This 
was done to make the study group as homogenous as possible and give the study strength. 
Recruitment was completed through flyers and social media posting on local cycling-club 
websites in Bergen, Norway. Since both the inclusion criteria and recruitment was narrow, 
several limitations did occur.  
 
Considering the small sample size with only men included in the study, findings cannot be 
generalized and might not be applicable to women. Furthermore, participants represented a part 
of the population with a high level of physical activity compared to the general population. 
High physical activity is related to increased muscle mass which could have impacted the effect 
of MPH.  The general population and most patient groups usually have a normal or below 
normal amount of muscle mass which could impact both synthesis and degradation of muscles 
differently.  
 
The original inclusion criteria with men between 40 to 50 years of age had to be extended to 40 
to 58 years. This was a consequence of few volunteers and a some withdraws during the 
recruitment period. Records of how many that were assessed during the recruitment or where 
participants were recruited from were not performed. As a result, there is no record of the 
amount of people reached, how they were reached or any information exceeding the fact that 




4.2.2 Study design  
The intervention was based on a double blind, randomized, placebo-controlled pilot study with 
crossover, divided into three phases. The reasoning the study design is its numerus strengths. 
First, double-blinding excludes any personal interest regarding the intervention or other bias 
that could occur with knowledge about the intervention drink or the placebo. Both drinks were 
delivered from the manufacture in opaque glass with white powder and marked with the letter 
A or B and the participants intervention number on the cover.  
 
Secondly, the randomization was performed by each participant individually. The first 
intervention day, each participant chose if they wanted to have the drink marked with letter A 
or B. They then received the opposite at the second intervention day. This way personal 
opinions about the drinks are limited. Also, it limits the influence of participants having a better 
knowledge the second time they go through the same testing. 
 
Thirdly, using cross-over were the participants act as their own control decreases differences in 
metabolism rates, muscle mass, performance etc. in between participants as it ensures a greater 
biological homogeneous sample.  
 
Another important factor of using this study design was the wash-out period. Considering the 
same participants received the two different drinks, a long enough wash-out period was crucial. 
As there was a risk of the carry-over effect between phase two and three that could have affected 
the second result, an estimated wash-out period based on animal-studies related to the nitrogen 
balance was used (55). This estimated period was based on the assumption that there would not 
be a difference in the carry-over effect between animals and humans, which could be a 
limitation.  
 
In addition, it is worth mentioning that this was a pilot study involving only a small study 
population which could both be a strength and limitation. Systematic errors and missing values 
may have had a significant impact on our findings, considering the collected data were so small 
and sensitive to each measure. The intervention would most likely have benefited from a wider 
inclusion of the population with a much larger sample size, even though this was not possible 




Intervention drinks were individualized by estimation of the protein requirements based on 
body mass in each participant as a strength to the study. However, the same measure was not 
possible to be performed in the standardized meals each participant received during test days. 
The same meals were served to all participants except for one participant that received another 
main meal (see section 2.3.4), making the individualized test drink differences too small to 
account for.  
 
There was only a small difference between the intervention drinks considering whey protein 
was the main protein source in both could be the main limitation of this study. A bigger 
difference between the drinks might have showed different results. In addition, only 3.2 E% in 
a single dose right after the first exhaustion cycling session was used. Several doses over a 
longer time period might also have influenced the results differently. However, this study 
focused on finding differences between a small dose of hydrolyzed protein compared to a more 
regular dose of whole protein.  
 
Restitution past challenging exercise sessions is dependent on several factors for the next 
48hours, where dietary intake is one main component in muscle synthesis and the rate of 
degradation. Collected data from 0- and 60 min past second session in blood combined with 
urine samples collected over a 9hour period will only represent the acute response and not the 
actual response of total synthesis and degradation. These limitations do probably have an 
impact on our findings, making our findings better fitted as indications rather than results of 
MPH.  
 
Nitrogen metabolized was analyzed by Nofima AS, while 1-MH, 3-MH and creatinine were 
analyzed by Bevital AS and CK measured at the Laboratory of Clinical Biochemestry. These 
operators all used standardized methods which insured high accuracy and contributed to a 
higher strength regarding the results. RBP4 was measured preforming the ELISA. A method 
with good strength and stability; however human errors could have occurred. There was only 
one kit available to perform the procedure, which also caused a limitation whereas a mean 
measure between two tests could have increased the reliability. In addition, several measures 
were outside the reference range. This would have been accounted for if the procedure had been 
performed a second time by using a less diluted sample. As there was not enough serum to 
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perform the ELISA after other analysis had been performed, we had to use plasma although 
previous studies usually used serum (10). This could also have had an impact on the results. 
 
It was decided that each participant would complete a diet registration from the last three days 
before phase two and one day before phase three. Because of many limitations to the recording, 
the data received was used as an indicator and not used in direct calculations. The inclusion of 
a complete diet registration could have been a good strength to the study, especially since 
several of the biomarkers used in this thesis are influenced by diet. 
  
4.2.4 Urine and blood sampling 
Each participant was allocated their individual time for both test days. All blood samples were 
collected by a qualified nurse following a standardized approach. Samples were collected 
through a peripheral venous catheter to ensure the collection of enough blood and accuracy 
which gave the sampling good strength. Because participants were given different timeslots, 
natural circadian rhythms in the human body could vary between participants which were not 
accounted for. 
Moreover, the estimated nitrogen balance through controlled intake of protein and urine 
collection over a 9hour period caused a weak indication of the true balance. Total collection of 
urine a few days before the intervention in addition to a longer collection period during the 
intervention would have given the results better strength. A more throughout dietary 
registration or controlled diet over a longer time period could also have been performed. Other 
studies have collected data during a longer period past performance, since restitution of muscle 
usually last and are still affected about 48hours after. The same with an accurate measure of 
protein intake (10). However, this collection would still only give a crude estimate of the true 
nitrogen balance, hence measuring nitrogen balance requires meticulous detail which was not 
possible to accomplish in this study. 
4.2.5 Biomarkers 
All parameters looked at in this thesis was not accounted for when the study took place but was 
decided to be used when the sample collection was complete. Consequently, important factors 
have been impacted and then corrugated as much as possible. One example was that 3-MH 
would not be an accurate measure if the participants had been eating meat a few days in 
advanced. In addition, the standardized meals during intervention day one and two both 
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contained meat. As mentioned earlier, other studies have showed that the calculated  1-MH/ 3-
MH ratio do give a good estimation of muscle degradation in humans with less interference 
from degradation of consumed meat (39, 40). This correction gave the results more strength 
and was a crucial part for the inclusion of these results.    
 
A second example is how nitrogen balance techniques are well known to overestimate nitrogen 
intake and underestimate nitrogen losses. Estimates are highly dependent on the assumed 
amount of nitrogen miscellaneous losses that are measured to be fairly constant (19). This study 
did not account for these losses in neither of the testing. The assessment of the nitrogen losses 
through the skin (urea), the loss of nitrogen gas after denitrification by the colonic microflora 
and in the expired air (ammonia) cannot be measured using the Kjeldahl method (31). This 
could have had an impact that should be accounted for, although such testing would have been 
too demanding for this study. 
 
4.3 FUTURE ASPECTS 
This study has demonstrated the need to further explore and investigate the use of MPH as a 
supplement to increase muscle synthesis and decrease muscle degradation in humans. Even 
though this study did not find any significant effect of a single small dose containing MPH on 
muscle synthesis and degradation, several results did suggest that there might be improvement 
through increased protein synthesis with the usage of MPH. 
 
To further explore this topic, several improvements to the limitations in this study should be 
corrected for. Recruitment of a more representing part of the general population with a bigger 
sample size would be recommended along with a more careful selection of participants. 
Multiple doses of MPH over a longer period could give better results. A longer measurement 
period with a more thoroughly collection of urine and blood samples could give more reliable 
measures especially concerning nitrogen metabolized, CK and 3-MH, in addition to a more 





Intake of MPH following exhaustive endurance cycling did not show any significant difference 
on biomarkers related to muscle synthesis and degradation. However, nitrogen retained in the 
body tended to be higher in the MPH group. Also, RBP4 measures of the total protein pool in 
the body seemed to have decreased levels following the MPH drink. These results could 
indicate a faster uptake of protein in the muscles supporting muscle synthesis. This study also 
found a higher 1-MH/ 3-MH ratio in both urine and plasma samples which indicated less 
excretion of 3-MH. This could imply a reduced muscle degradation following the MPH drink.  
 
In this study, the decreased results of CK, 1-MH/ 3-MH and 3-MH/ Creatinine levels suggest a 
temporary failure of muscle synthesis rather than decreased muscle degradation. Identification 
of the catabolic contribution to overall protein degradation could therefore be less important 
during muscle wasting than increasing protein synthesis. As such, a possible way to prevent 
catabolic diseases could be to further study potential solutions to increase protein synthesis. 
 
Considering that this thesis did not achieve significant results, there is no evidence that MPH 
have an impact on biomarkers related to muscle synthesis and degradation. On this basis, H1 is 
rejected while H0 is proven, stating that the intake of a single dose of 20 mg/kg BW of MPH 
did not show significant impact on biomarkers related to muscle synthesis and degradation in 
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19. Tomé D, Bos Cc. Dietary Protein and Nitrogen Utilization. The Journal of nutrition. 
2000;130(7):1868S-73S. 
20. Munro HN. Nutrition and muscle protein metabolism: Introduction. Federation 
proceedings. 1978;37(9):2281-2. 
21. Witard OC, Wardle SL, Macnaughton LS, Hodgson AB, Tipton KD. Protein 
Considerations for Optimising Skeletal Muscle Mass in Healthy Young and Older Adults. 
Nutrients. 2016;8(4):181. 
22. Chou CJ, Affolter M, Kussmann M. A nutrigenomics view of protein intake: 
macronutrient, bioactive peptides, and protein turnover. Progress in molecular biology and 
translational science. 2012;108:51-74. 
23. Hellerstein MK, Munro, H.N. Interaction of liver and muscle in the regulation of 
metabolism in response to nutritional and other factors. In the liver. Biology and Pathobiology. 
1988;2nd edition:965-83. 
24. Berg JM TJ, Stryer L. Proetin structure and function. In: W.H. F, editor. Biochemistry. 
New York2002. 
25. Hoffman JR, Falvo MJ. Protein - Which is Best? Journal of sports science & medicine. 
2004;3(3):118-30. 
26. Van De Walle G. 9 Important functions of protein in your body Healthline: Healthline; 
2018 [Available from: https://www.healthline.com/nutrition/functions-of-protein. 
27. Barmore W, Stone WL. Physiology, Urea Cycle.  StatPearls. Treasure Island (FL): 
StatPearls Publishing 
StatPearls Publishing LLC.; 2019. 
28. Identifying patients at risk: ADA's definitions for nutrition screening and nutrition 
assessment. Council on Practice (COP) Quality Management Committee. Journal of the 
American Dietetic Association. 1994;94(8):838-9. 
29. Buchholz AC, Bartok C, Schoeller DA. The validity of bioelectrical impedance models in 
clinical populations. Nutrition in clinical practice : official publication of the American Society 
for Parenteral and Enteral Nutrition. 2004;19(5):433-46. 
30. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, et al. Bioelectrical 
impedance analysis--part I: review of principles and methods. Clinical nutrition (Edinburgh, 
Scotland). 2004;23(5):1226-43. 
31. Tessari P. Nitrogen Balance and Protein Requirements: Definition 
and Measurements. In: Cachexia and Wasting: A Modern Approach [Internet]. [73-9]. 
Available from: https://link-springer-com.pva.uib.no/book/10.1007%2F978-88-470-0552-5. 
32. Anonymous. Energy and protein requirements. Wordl health organ: FAO/WHO/UNU 
Expert consultation; 1985. 
33. Price SR, Mitch WE. Metabolic acidosis and uremic toxicity: protein and amino acid 
metabolism. Seminars in nephrology. 1994;14(3):232-7. 
34. Motil KJ, Matthews DE, Bier DM, Burke JF, Munro HN, Young VR. Whole-body leucine 
and lysine metabolism: response to dietary protein intake in young men. The American journal 
of physiology. 1981;240(6):E712-21. 
35. Calloway DH, Margen S. Variation in Endogenous Nitrogen Excretion and Dietary 




36. Cabaniss DC. Creatine Kinase.  Clinical Methods: The history, Physical, and Laboratory 
Examinations 3 rd edition. Boston: Butterworths; 1990. 
37. AACC. Creatine Kinase (CK) Lab tests online - Your trusted guide2016 [Available from: 
https://labtestsonline.org/tests/creatine-kinase-ck. 
38. Johnson P, Harris CI, Perry SV. 3-methylhistidine in actin and other muscle proteins. 
The Biochemical journal. 1967;105(1):361-70. 
39. Sjolin J, Hjort G, Friman G, Hambraeus L. Urinary excretion of 1-methylhistidine: a 
qualitative indicator of exogenous 3-methylhistidine and intake of meats from various 
sources. Metabolism: clinical and experimental. 1987;36(12):1175-84. 
40. Bevital. 3-Methylhistidine and 1-methylhistidine Bergen: Bevital;  [Available from: 
https://folk.uib.no/mfapu/Pages/BV/BVSite/analyteinfo/mHist.html. 
41. Elia M, Carter A, Bacon S, Winearls CG, Smith R. Clinical usefulness of urinary 3-
methylhistidine excretion in indicating muscle protein breakdown. British medical journal 
(Clinical research ed). 1981;282(6261):351-4. 
42. Lukaski HC, Mendez J, Buskirk ER, Cohn SH. Relationship between endogenous 3-
methylhistidine excretion and body composition. The American journal of physiology. 
1981;240(3):E302-7. 
43. VM S. Fundementals of nutrition.  Introduction to clinical nutrition. New York1998. p. 
1-13. 
44. Sjolin J, Stjernstrom H, Henneberg S, Andersson E, Martensson J, Friman G, et al. 
Splanchnic and peripheral release of 3-methylhistidine in relation to its urinary excretion in 
human infection. Metabolism: clinical and experimental. 1989;38(1):23-9. 
45. Tipton KD, Hamilton DL, Gallagher IJ. Assessing the Role of Muscle Protein Breakdown 
in Response to Nutrition and Exercise in Humans. Sports medicine (Auckland, NZ). 
2018;48(Suppl 1):53-64. 
46. Goodman DS. Retinoid-binding proteins. Journal of the American Academy of 
Dermatology. 1982;6(4 Pt 2 Suppl):583-90. 
47. Hsiung TP. Protein Assessment 2016 [Available from: 
http://www.tomhsiung.com/wordpress/2016/08/biochemical-assessment-of-nutrition-
status/. 
48. Ong DE. Cellular retinoid-binding proteins. Archives of dermatology. 
1987;123(12):1693-5a. 
49. Miura N, Kitamura H, Kameko M. [Evaluation of the reference range of retinol-binding 
protein (RBP) levels by the latex turbidimetric immunoassay]. Rinsho byori The Japanese 
journal of clinical pathology. 2009;57(3):195-9. 
50. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol 
binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 
2005;436(7049):356-62. 
51. Advances R. Marine protein hydrolysates: their present and future perspectives in food 
chemistry – A review. RSC Advances. 2013;1(1):1-100. 
52. Aadland EK, Lavigne C, Graff IE, Eng O, Paquette M, Holthe A, et al. Lean-seafood intake 
reduces cardiovascular lipid risk factors in healthy subjects: results from a randomized 
controlled trial with a crossover design. The American journal of clinical nutrition. 
2015;102(3):582-92. 
53. Nobile V, Duclos E, Michelotti A, Bizzaro G, Negro M, Soisson F. Supplementation with 
a fish protein hydrolysate (Micromesistius poutassou): effects on body weight, body 
composition, and CCK/GLP-1 secretion. Food & nutrition research. 2016;60:29857. 
69 
 
54. Manninen AH. Protein hydrolysates in sports nutrition. Nutrition & metabolism. 
2009;6:38. 
55. Poullain MG, Cezard JP, Roger L, Mendy F. Effect of whey proteins, their oligopeptide 
hydrolysates and free amino acid mixtures on growth and nitrogen retention in fed and 
starved rats. JPEN Journal of parenteral and enteral nutrition. 1989;13(4):382-6. 
56. Hays NP, Kim H, Wells AM, Kajkenova O, Evans WJ. Effects of whey and fortified 
collagen hydrolysate protein supplements on nitrogen balance and body composition in older 
women. Journal of the American Dietetic Association. 2009;109(6):1082-7. 
57. Koopman R, Crombach N, Gijsen AP, Walrand S, Fauquant J, Kies AK, et al. Ingestion of 
a protein hydrolysate is accompanied by an accelerated in vivo digestion and absorption rate 
when compared with its intact protein. The American journal of clinical nutrition. 
2009;90(1):106-15. 
58. Manninen AH. Protein hydrolysates in sports and exercise: a brief review. Journal of 
sports science & medicine. 2004;3(2):60-3. 
59. Cheung RC, Ng TB, Wong JH. Marine Peptides: Bioactivities and Applications. Marine 
drugs. 2015;13(7):4006-43. 
60. Miguel M. CM, Recio I., Aleixandre A. . Food Chemistry. 2009. p. 211-4. 
61. Lavigne C, Marette A, Jacques H. Cod and soy proteins compared with casein improve 
glucose tolerance and insulin sensitivity in rats. American journal of physiology Endocrinology 
and metabolism. 2000;278(3):E491-500. 
62. Lavigne C, Tremblay F, Asselin G, Jacques H, Marette A. Prevention of skeletal muscle 
insulin resistance by dietary cod protein in high fat-fed rats. American journal of physiology 
Endocrinology and metabolism. 2001;281(1):E62-71. 
63. Ullrich SS, Fitzgerald PC, Schober G, Steinert RE, Horowitz M, Feinle-Bisset C. 
Intragastric administration of leucine or isoleucine lowers the blood glucose response to a 
mixed-nutrient drink by different mechanisms in healthy, lean volunteers. The American 
journal of clinical nutrition. 2016;104(5):1274-84. 
64. Siegler JC, Page R, Turner M, Mitchell N, Midgely AW. The effect of carbohydrate and 
marine peptide hydrolysate co-ingestion on endurance exercise metabolism and 
performance. Journal of the International Society of Sports Nutrition. 2013;10:29. 
65. Vegge G, Ronnestad BR, Ellefsen S. Improved cycling performance with ingestion of 
hydrolyzed marine protein depends on performance level. Journal of the International Society 
of Sports Nutrition. 2012;9(1):14. 
66. Vikoren LA, Nygard OK, Lied E, Rostrup E, Gudbrandsen OA. A randomised study on the 
effects of fish protein supplement on glucose tolerance, lipids and body composition in 
overweight adults. The British journal of nutrition. 2013;109(4):648-57. 
67. K. SE. Encyclopaedia of Occipational Health and Safety.  Encyclopaedia of Occipational 
Health and Safety. 
68. Venkatesan J, Anil S, Kim SK, Shim MS. Marine Fish Proteins and Peptides for 
Cosmeceuticals: A Review. Marine drugs. 2017;15(5). 
69. AS F. Biff Stroganoff: Fjordland AS;  [Available from: 
https://www.fjordland.no/produkter/kjott/biff-stroganoff. 
70. AS F. Torsk med purreløksaus, gulrøtter og poteter  [Available from: 
https://www.fjordland.no/produkter/fisk/torsk. 
71. AS N. Nofima AS  [Available from: https://nofima.no/. 
70 
 
72. Midttun O, Kvalheim G, Ueland PM. High-throughput, low-volume, multianalyte 
quantification of plasma metabolites related to one-carbon metabolism using HPLC-MS/MS. 
Analytical and bioanalytical chemistry. 2013;405(6):2009-17. 
73. Analyseoversikten. CK: Helse Bergen HF Haukeland universitetssjukehus;  [cited 2019 
26.03]. Available from: https://analyseoversikten.no/analyse/166. 
74. science ML. The principle and method of ELISA ruo.mbl.co.jp [cited 2019 03.26]. 
Available from: http://ruo.mbl.co.jp/bio/e/support/method/elisa.html. 
75. Sergi G, Coin A, Enzi G, Volpato S, Inelmen EM, Buttarello M, et al. Role of visceral 
proteins in detecting malnutrition in the elderly. European journal of clinical nutrition. 
2006;60(2):203-9. 
76. Paul GL, DeLany JP, Snook JT, Seifert JG, Kirby TE. Serum and urinary markers of skeletal 
muscle tissue damage after weight lifting exercise. European journal of applied physiology and 
occupational physiology. 1989;58(7):786-90. 
77. Seashore JH, Huszar G, Davis EM. Urinary 3-methylhistidine/creatinine ratio as a 
clinical tool: correlation between 3-methylhistidine excretion and metabolic and clinical states 
in healthy and stressed premature infants. Metabolism: clinical and experimental. 
1981;30(10):959-69. 
78. Buckley JD, Thomson RL, Coates AM, Howe PR, DeNichilo MO, Rowney MK. 
Supplementation with a whey protein hydrolysate enhances recovery of muscle force-
generating capacity following eccentric exercise. Journal of science and medicine in sport. 
2010;13(1):178-81. 
79. Baird MF, Graham SM, Baker JS, Bickerstaff GF. Creatine-kinase- and exercise-related 
muscle damage implications for muscle performance and recovery. Journal of nutrition and 
metabolism. 2012;2012:960363. 
80. Dohm GL, Kasperek GJ, Tapscott EB, Beecher GR. Effect of exercise on synthesis and 






























































APPENDIX 4. NITROGEN INTAKE METABOLIZED AND RETAINED 
FOLLOWING MPH AND PLACEBO DRINK IN EACH PARTICIPANT. 
 
 
Nitrogen intake, metabolized and retained after consuming MPH drink. 
Nitrogen intake estimated from controlled intake throughout the day. Nitrogen metabolized and 
retained nitrogen measured in urine samples after intake of MPH over a 9 hour period in each 
participant. 
 
Nitrogen intake, metabolized and retained after consuming placebo drink. 
Nitrogen intake estimated from controlled intake throughout the day. Nitrogen metabolized and 
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Comparing nitrogen metabolized presented as analyte level in total amount of urine from 
each participant between drinks. 
Measured in urine samples after intake of MPH and placebo post exhaustion endurance cycling 

























































































































1 2 3 4 5 6 7 8 9 10 11 12 13 14
MPH Placebo
Nitrogen metabolized (gram) per viral ID 
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1-MH/ 3-MH ratio from both MPH and placebo drink. 
Measured in urine samples after intake of either MPH or placebo post exhaustion endurance 
cycling collected over a period of 9hours in each participant.  
 
 
3-MH/ Creatinine ratio from both MPH and placebo drink. 
Measured in urine samples after intake of either MPH or placebo post exhaustion endurance 
cycling collected over a period of 9hours in each participant. 3-MH used is the true value 
representing the 1-MH/ 3-MH ratio.  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
MPH 2,40 1,85 1,19 0,72 6,85 1,26 0,48 2,25 0,46 0,46








3,50 1-MH/3-MH per viral ID 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
MPH 0,54 0,13 0,13 0,08 1,47 0,25 0,05 0,37 0,05 0,04











APPENDIX 6. CORRELATION ANALYSIS. 
Correlations between nitrogen in urine and the other biomarkers in plasma/ serum 
following MPH. 
MPH Nitrogen 1 3-MH2/ Creatinine CK RBP4 
Nitrogen 1     
Coefficient X -0.103 0.248 0.405 
P-value X 0.777 0.489 0.320 
3-MH2/ Creatinine     
Coefficient -0.103 X -0.382 -0.333 
P-value 0.777 X 0.276 0.420 
CK     
Coefficient 0.248 -0.382 X 0.548 
P-value 0.489 0.276 X 0.160 
RBP4     
Coefficient 0.405 -0.333 0.548 X 
P-value 0.320 0.420 0.160 X 
*Statistical significance was evaluated using two-sided pair wise t-test accepting P < 0.05 as 
significant. 
1 Nitrogen metabolized.  
2 1-MH/ 3-MH 
 
Correlations between nitrogen in urine and the other biomarkers in plasma/ serum 
following placebo. 
Placebo Nitrogen 1 3-MH2/ Creatinine CK RBP4 
Nitrogen 1     
Coefficient X -0.203 -0.042 -0.345 
P-value X 0.527 0.897 0.298 
3-MH2/ Creatinine     
Coefficient -0.203 X -0.021 0.164 
P-value 0.527 X 0.948 0.631 
CK     
Coefficient -0.042 -0.021 X -0.028 
P-value 0.897 0.948 X 0.931 
RBP4     
Coefficient -0.345 0.164 -0.028 X 
P-value 0.298 0.631 0.931 X 
*Statistical significance was evaluated using two-sided pair wise t-test accepting P < 0.05 as 
significant. 
1 Nitrogen metabolized.  
2 1-MH/ 3-MH 
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APPENDIX 9. VAS OF GASTRO INTESTINAL SYMPTOMS.  
 
 
 
 
